https://trial.medpath.com/news/phoremost-unveils-lead-oncology-candidate-pmc-001-a-next-generation-oral-microtubule-targeting-agent-for-brain-cancers-and-appoints-chief-medical-officer 2026-06-10T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoremost-unveils-lead-oncology-candidate-pmc-001-a-next-generation-oral-microtubule-targeting-agent-for-brain-cancers-and-appoints-chief-medical-officer 2026-06-10T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-and-kite-pharma-partner-to-expand-u-s-distribution-of-car-t-cell-therapies 2026-06-10T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cencora-and-kite-pharma-partner-to-expand-u-s-distribution-of-car-t-cell-therapies 2026-06-10T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/columbia-s-irving-institute-secures-75-million-ctsa-renewal-to-advance-ai-driven-translational-research 2026-06-10T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/columbia-s-irving-institute-secures-75-million-ctsa-renewal-to-advance-ai-driven-translational-research 2026-06-10T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/mindwalk-launches-reefiq-a-biological-context-layer-to-power-ai-driven-drug-discovery 2026-06-10T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindwalk-launches-reefiq-a-biological-context-layer-to-power-ai-driven-drug-discovery 2026-06-10T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/actor-tyler-mane-reveals-male-breast-cancer-diagnosis-urges-men-to-seek-early-screening 2026-06-10T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actor-tyler-mane-reveals-male-breast-cancer-diagnosis-urges-men-to-seek-early-screening 2026-06-10T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/erc-awards-eur150000-proof-of-concept-grant-to-gustave-roussy-s-nano-bite-project-for-nanomedicine-enhanced-immunotherapy-against-solid-tumors 2026-06-10T17:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erc-awards-eur150000-proof-of-concept-grant-to-gustave-roussy-s-nano-bite-project-for-nanomedicine-enhanced-immunotherapy-against-solid-tumors 2026-06-10T17:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-langone-health-receives-15-million-philanthropic-gift-to-expand-autoimmune-disease-research-consortium 2026-06-10T16:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-langone-health-receives-15-million-philanthropic-gift-to-expand-autoimmune-disease-research-consortium 2026-06-10T16:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-repurposing-market-to-reach-10-56-billion-by-2035-growing-at-23-4-cagr 2026-06-10T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-drug-repurposing-market-to-reach-10-56-billion-by-2035-growing-at-23-4-cagr 2026-06-10T16:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/huck-institutes-awards-nine-interdisciplinary-seed-grants-for-2026-27-including-novel-aml-immunotherapy-and-pediatric-asthma-research 2026-06-10T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huck-institutes-awards-nine-interdisciplinary-seed-grants-for-2026-27-including-novel-aml-immunotherapy-and-pediatric-asthma-research 2026-06-10T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/why-pilots-don-t-scale-the-case-for-pre-protocol-invariants-in-clinical-development 2026-06-10T16:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/why-pilots-don-t-scale-the-case-for-pre-protocol-invariants-in-clinical-development 2026-06-10T16:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-americans-primarily-blame-insurers-for-rising-healthcare-costs-sparking-industry-debate 2026-06-10T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-americans-primarily-blame-insurers-for-rising-healthcare-costs-sparking-industry-debate 2026-06-10T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/daily-sugar-sweetened-beverage-intake-linked-to-higher-risk-of-liver-and-gastric-cancers 2026-06-10T15:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-sugar-sweetened-beverage-intake-linked-to-higher-risk-of-liver-and-gastric-cancers 2026-06-10T15:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fostrox-plus-lenvatinib-shows-promising-efficacy-and-safety-in-advanced-liver-cancer-published-in-clinical-cancer-research 2026-06-10T15:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fostrox-plus-lenvatinib-shows-promising-efficacy-and-safety-in-advanced-liver-cancer-published-in-clinical-cancer-research 2026-06-10T15:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/developmental-and-epileptic-encephalopathies-market-poised-for-11-7-cagr-growth-through-2036-driven-by-next-generation-gene-and-targeted-therapies 2026-06-10T15:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/developmental-and-epileptic-encephalopathies-market-poised-for-11-7-cagr-growth-through-2036-driven-by-next-generation-gene-and-targeted-therapies 2026-06-10T15:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/house-fy-2027-bill-boosts-amr-and-niaid-funding-but-workforce-and-hiv-cuts-raise-alarm 2026-06-10T15:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/house-fy-2027-bill-boosts-amr-and-niaid-funding-but-workforce-and-hiv-cuts-raise-alarm 2026-06-10T15:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/unisom-expands-into-wellness-supplements-with-drug-free-magnesium-ashwagandha-sleep-gummies 2026-06-10T15:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unisom-expands-into-wellness-supplements-with-drug-free-magnesium-ashwagandha-sleep-gummies 2026-06-10T15:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/source-materials-unavailable-no-verifiable-pharmaceutical-r-d-content-to-report 2026-06-10T15:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/source-materials-unavailable-no-verifiable-pharmaceutical-r-d-content-to-report 2026-06-10T15:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-doses-first-patient-with-cellular-reprogramming-therapy-for-glaucoma-eyes-broader-anti-aging-potential 2026-06-10T15:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-biosciences-doses-first-patient-with-cellular-reprogramming-therapy-for-glaucoma-eyes-broader-anti-aging-potential 2026-06-10T15:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/us-cardiovascular-drugs-market-projected-to-reach-37-03-billion-by-2035-driven-by-rna-therapeutics-and-ai-powered-drug-discovery 2026-06-10T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-cardiovascular-drugs-market-projected-to-reach-37-03-billion-by-2035-driven-by-rna-therapeutics-and-ai-powered-drug-discovery 2026-06-10T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/hkeybio-launches-nhp-fast-poc-program-to-deliver-low-cost-cyno-pk-pd-and-developability-data-amid-rising-nhp-prices 2026-06-10T15:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkeybio-launches-nhp-fast-poc-program-to-deliver-low-cost-cyno-pk-pd-and-developability-data-amid-rising-nhp-prices 2026-06-10T15:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-tofidence-indications-to-include-car-t-cytokine-release-syndrome-and-pediatric-covid-19 2026-06-10T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-tofidence-indications-to-include-car-t-cytokine-release-syndrome-and-pediatric-covid-19 2026-06-10T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-to-raise-awareness-of-treatable-obstructive-sleep-apnea-in-adults-with-obesity 2026-06-10T15:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-to-raise-awareness-of-treatable-obstructive-sleep-apnea-in-adults-with-obesity 2026-06-10T15:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-holdings-makes-first-european-biotech-investment-backing-clearidebio-s-next-generation-adc-pipeline 2026-06-10T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotte-holdings-makes-first-european-biotech-investment-backing-clearidebio-s-next-generation-adc-pipeline 2026-06-10T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/servier-enrolls-first-patient-in-phase-ib-ii-trial-of-aso-therapy-for-kcnt1-related-pediatric-epilepsy 2026-06-10T14:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-enrolls-first-patient-in-phase-ib-ii-trial-of-aso-therapy-for-kcnt1-related-pediatric-epilepsy 2026-06-10T14:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/sophia-genetics-shareholders-approve-leadership-transition-ross-muken-to-become-ceo-co-founder-jurgi-camblong-elected-executive-chairman 2026-06-10T14:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sophia-genetics-shareholders-approve-leadership-transition-ross-muken-to-become-ceo-co-founder-jurgi-camblong-elected-executive-chairman 2026-06-10T14:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/tracelink-wins-ism-supply-chain-trailblazer-award-for-opus-platform-advancing-agentic-supply-chain-operations-in-life-sciences 2026-06-10T14:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tracelink-wins-ism-supply-chain-trailblazer-award-for-opus-platform-advancing-agentic-supply-chain-operations-in-life-sciences 2026-06-10T14:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/biosimilars-cut-cancer-drug-costs-by-3820-monthly-for-insurers-ucla-study-finds 2026-06-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosimilars-cut-cancer-drug-costs-by-3820-monthly-for-insurers-ucla-study-finds 2026-06-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/roquette-showcases-scalable-drug-delivery-innovations-at-cphi-china-2026 2026-06-10T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roquette-showcases-scalable-drug-delivery-innovations-at-cphi-china-2026 2026-06-10T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/ethyreal-bio-launches-with-101-million-to-advance-dual-targeting-tshr-antibody-for-graves-disease-and-thyroid-eye-disease 2026-06-10T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethyreal-bio-launches-with-101-million-to-advance-dual-targeting-tshr-antibody-for-graves-disease-and-thyroid-eye-disease 2026-06-10T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/orionis-biosciences-and-novartis-expand-collaboration-to-develop-molecular-glue-drugs-using-ai-driven-platform 2026-06-10T13:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orionis-biosciences-and-novartis-expand-collaboration-to-develop-molecular-glue-drugs-using-ai-driven-platform 2026-06-10T13:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/physician-compensation-rises-in-2025-but-real-pay-stagnates-as-productivity-gains-drive-growth 2026-06-10T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physician-compensation-rises-in-2025-but-real-pay-stagnates-as-productivity-gains-drive-growth 2026-06-10T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-wearable-health-data-deluge-why-doctors-are-struggling-to-keep-up-with-streaming-patient-metrics 2026-06-10T11:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-wearable-health-data-deluge-why-doctors-are-struggling-to-keep-up-with-streaming-patient-metrics 2026-06-10T11:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/marathon-running-triggers-acute-cardiac-biomarker-spikes-and-structural-changes-but-long-term-clinical-significance-remains-unclear 2026-06-10T11:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marathon-running-triggers-acute-cardiac-biomarker-spikes-and-structural-changes-but-long-term-clinical-significance-remains-unclear 2026-06-10T11:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/cro-and-sponsor-m-a-disruptions-the-operational-toll-on-clinical-trial-sites 2026-06-10T11:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cro-and-sponsor-m-a-disruptions-the-operational-toll-on-clinical-trial-sites 2026-06-10T11:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/person-centered-contraceptive-counseling-and-access-support-dramatically-narrow-effectiveness-gaps-between-birth-control-methods 2026-06-10T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/person-centered-contraceptive-counseling-and-access-support-dramatically-narrow-effectiveness-gaps-between-birth-control-methods 2026-06-10T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/higher-bmi-reduces-effectiveness-of-jak-inhibitors-in-rheumatoid-arthritis 2026-06-10T09:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-bmi-reduces-effectiveness-of-jak-inhibitors-in-rheumatoid-arthritis 2026-06-10T09:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-semaglutide-shows-early-promise-for-improving-fertility-in-women-with-pmos-proof-of-concept-study-finds 2026-06-10T09:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-semaglutide-shows-early-promise-for-improving-fertility-in-women-with-pmos-proof-of-concept-study-finds 2026-06-10T09:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-halts-mobilize-phase-3-trial-of-riliprubart-in-refractory-cidp-after-interim-analysis-shows-insufficient-efficacy 2026-06-10T09:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-halts-mobilize-phase-3-trial-of-riliprubart-in-refractory-cidp-after-interim-analysis-shows-insufficient-efficacy 2026-06-10T09:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-engineering-cell-therapies-across-oncology-genetic-disorders-and-autoimmune-disease 2026-06-10T08:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-engineering-cell-therapies-across-oncology-genetic-disorders-and-autoimmune-disease 2026-06-10T08:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/from-approval-to-adoption-why-biotech-s-greatest-challenge-lies-beyond-the-lab 2026-06-10T06:56:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-approval-to-adoption-why-biotech-s-greatest-challenge-lies-beyond-the-lab 2026-06-10T06:56:10+00:00 hourly 0.9 https://trial.medpath.com/news/rege-nephro-a-cira-spin-off-pioneering-ips-cell-therapies-for-kidney-disease 2026-06-10T06:56:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rege-nephro-a-cira-spin-off-pioneering-ips-cell-therapies-for-kidney-disease 2026-06-10T06:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/slc6a20-targeting-aso-restores-nmda-receptor-function-in-autism-models-offering-new-therapeutic-strategy 2026-06-10T06:54:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/slc6a20-targeting-aso-restores-nmda-receptor-function-in-autism-models-offering-new-therapeutic-strategy 2026-06-10T06:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/kdca-unveils-comprehensive-pandemic-preparedness-plan-with-mrna-vaccine-localization-target-by-2028 2026-06-10T06:54:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kdca-unveils-comprehensive-pandemic-preparedness-plan-with-mrna-vaccine-localization-target-by-2028 2026-06-10T06:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-clinical-guideline-unifies-care-for-cardiovascular-kidney-metabolic-syndrome 2026-06-10T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ever-clinical-guideline-unifies-care-for-cardiovascular-kidney-metabolic-syndrome 2026-06-10T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-alternative-funding-programs-to-treatment-delays-as-black-market-for-investigational-weight-loss-drugs-surges 2026-06-10T05:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-alternative-funding-programs-to-treatment-delays-as-black-market-for-investigational-weight-loss-drugs-surges 2026-06-10T05:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/mind-diet-emerges-as-leading-evidence-based-dietary-strategy-for-dementia-prevention 2026-06-10T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mind-diet-emerges-as-leading-evidence-based-dietary-strategy-for-dementia-prevention 2026-06-10T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-map-of-healthy-pancreas-reveals-origins-of-aggressive-tumors-challenging-one-size-fits-all-treatment 2026-06-10T03:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-map-of-healthy-pancreas-reveals-origins-of-aggressive-tumors-challenging-one-size-fits-all-treatment 2026-06-10T03:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/hybrid-nanotheranostics-integrating-magnetic-luminescent-and-nanobody-platforms-for-next-generation-precision-oncology 2026-06-10T00:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hybrid-nanotheranostics-integrating-magnetic-luminescent-and-nanobody-platforms-for-next-generation-precision-oncology 2026-06-10T00:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/telephone-based-weight-loss-intervention-improves-physical-function-and-quality-of-life-in-early-stage-breast-cancer 2026-06-10T00:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telephone-based-weight-loss-intervention-improves-physical-function-and-quality-of-life-in-early-stage-breast-cancer 2026-06-10T00:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/dental-medicine-emerges-as-critical-partner-in-head-and-neck-cancer-care-at-cu-anschutz 2026-06-10T00:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dental-medicine-emerges-as-critical-partner-in-head-and-neck-cancer-care-at-cu-anschutz 2026-06-10T00:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/solid-phase-synthesis-of-tetradvp-linkers-enables-precise-scalable-antibody-bioconjugation-without-genetic-engineering 2026-06-10T00:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-phase-synthesis-of-tetradvp-linkers-enables-precise-scalable-antibody-bioconjugation-without-genetic-engineering 2026-06-10T00:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/how-a-rare-kidney-disease-gained-a-robust-new-therapy-pipeline 2026-06-09T23:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-a-rare-kidney-disease-gained-a-robust-new-therapy-pipeline 2026-06-09T23:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/geisel-school-of-medicine-welcomes-jennifer-hunt-as-first-woman-dean-in-229-year-history 2026-06-09T23:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geisel-school-of-medicine-welcomes-jennifer-hunt-as-first-woman-dean-in-229-year-history 2026-06-09T23:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/watchmaker-genomics-to-debut-crispr-based-library-normalization-and-high-fidelity-amplification-technologies-at-eshg-2026 2026-06-09T23:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/watchmaker-genomics-to-debut-crispr-based-library-normalization-and-high-fidelity-amplification-technologies-at-eshg-2026 2026-06-09T23:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/brigham-and-women-s-hospital-nurses-vote-99-6-to-authorize-strike-largest-rn-strike-vote-in-massachusetts-history 2026-06-09T23:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brigham-and-women-s-hospital-nurses-vote-99-6-to-authorize-strike-largest-rn-strike-vote-in-massachusetts-history 2026-06-09T23:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/metastatic-male-breast-cancer-a-90-year-old-s-journey-highlights-advances-in-targeted-therapy 2026-06-09T22:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metastatic-male-breast-cancer-a-90-year-old-s-journey-highlights-advances-in-targeted-therapy 2026-06-09T22:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/antogen-secures-seed-financing-to-advance-next-generation-immune-surveillance-diagnostics 2026-06-09T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antogen-secures-seed-financing-to-advance-next-generation-immune-surveillance-diagnostics 2026-06-09T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/how-hydroxyurea-and-longitudinal-research-are-transforming-pediatric-sickle-cell-disease-care 2026-06-09T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-hydroxyurea-and-longitudinal-research-are-transforming-pediatric-sickle-cell-disease-care 2026-06-09T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/ifpma-calls-for-practical-pathogen-access-system-as-ebola-and-hantavirus-outbreaks-expose-pandemic-preparedness-gaps 2026-06-09T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ifpma-calls-for-practical-pathogen-access-system-as-ebola-and-hantavirus-outbreaks-expose-pandemic-preparedness-gaps 2026-06-09T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/challenge-trial-structured-exercise-cuts-colon-cancer-recurrence-risk-by-28-landmark-study-finds 2026-06-09T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/challenge-trial-structured-exercise-cuts-colon-cancer-recurrence-risk-by-28-landmark-study-finds 2026-06-09T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/drug-free-nanoparticles-halt-triple-negative-breast-cancer-by-reprogramming-the-tumor-microenvironment 2026-06-09T21:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-free-nanoparticles-halt-triple-negative-breast-cancer-by-reprogramming-the-tumor-microenvironment 2026-06-09T21:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/asco-commends-house-appropriations-committee-for-prioritizing-cancer-research-in-fy27-spending-bill 2026-06-09T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-commends-house-appropriations-committee-for-prioritizing-cancer-research-in-fy27-spending-bill 2026-06-09T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-geometry-how-biomarkers-and-ai-are-redefining-personalization-in-radiation-oncology 2026-06-09T20:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-geometry-how-biomarkers-and-ai-are-redefining-personalization-in-radiation-oncology 2026-06-09T20:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/unr-med-resident-research-day-highlights-hematologic-premalignancy-research-and-vaccine-effectiveness-studies 2026-06-09T20:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unr-med-resident-research-day-highlights-hematologic-premalignancy-research-and-vaccine-effectiveness-studies 2026-06-09T20:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-senior-amadu-tadesse-earns-fulbright-to-build-ethiopia-s-first-national-pediatric-cancer-registry 2026-06-09T20:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-senior-amadu-tadesse-earns-fulbright-to-build-ethiopia-s-first-national-pediatric-cancer-registry 2026-06-09T20:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/latent-ebv-infection-enhances-anti-cd3-antibody-efficacy-in-type-1-diabetes 2026-06-09T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latent-ebv-infection-enhances-anti-cd3-antibody-efficacy-in-type-1-diabetes 2026-06-09T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/thx-pharma-and-exeltis-secure-ema-paediatric-committee-approval-for-tx01-unlocking-puma-pathway-for-niemann-pick-type-c-disease 2026-06-09T19:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thx-pharma-and-exeltis-secure-ema-paediatric-committee-approval-for-tx01-unlocking-puma-pathway-for-niemann-pick-type-c-disease 2026-06-09T19:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-launches-lenivia-a-new-monoclonal-antibody-for-canine-osteoarthritis-amid-companion-animal-portfolio-expansion 2026-06-09T19:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoetis-launches-lenivia-a-new-monoclonal-antibody-for-canine-osteoarthritis-amid-companion-animal-portfolio-expansion 2026-06-09T19:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/veterinary-drugs-market-to-reach-121-2-billion-by-2034-driven-by-biologics-innovation-and-preventive-care-shift 2026-06-09T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veterinary-drugs-market-to-reach-121-2-billion-by-2034-driven-by-biologics-innovation-and-preventive-care-shift 2026-06-09T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/how-body-temperature-and-calcium-levels-can-flip-a-drug-s-effect-northwestern-study-reveals-hidden-dimension-of-pharmacology 2026-06-09T18:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-body-temperature-and-calcium-levels-can-flip-a-drug-s-effect-northwestern-study-reveals-hidden-dimension-of-pharmacology 2026-06-09T18:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-school-of-medicine-honors-faculty-educators-and-celebrates-55th-graduating-class 2026-06-09T18:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-school-of-medicine-honors-faculty-educators-and-celebrates-55th-graduating-class 2026-06-09T18:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/albert-einstein-college-of-medicine-launches-bio-vital-to-accelerate-gerotherapeutics-development 2026-06-09T18:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/albert-einstein-college-of-medicine-launches-bio-vital-to-accelerate-gerotherapeutics-development 2026-06-09T18:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-3d-bioprinting-platform-accelerates-cancer-drug-testing-using-patient-derived-organoids 2026-06-09T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-3d-bioprinting-platform-accelerates-cancer-drug-testing-using-patient-derived-organoids 2026-06-09T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/prostate-cancer-foundation-launches-31st-annual-home-run-challenge-highlighting-progress-in-research-and-urgency-of-early-detection 2026-06-09T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prostate-cancer-foundation-launches-31st-annual-home-run-challenge-highlighting-progress-in-research-and-urgency-of-early-detection 2026-06-09T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-gen1e-s-gen-1123-for-duchenne-muscular-dystrophy 2026-06-09T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-gen1e-s-gen-1123-for-duchenne-muscular-dystrophy 2026-06-09T17:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/genome-wide-meta-analysis-identifies-80-variants-across-74-loci-for-generalized-anxiety-symptom-severity 2026-06-09T17:40:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genome-wide-meta-analysis-identifies-80-variants-across-74-loci-for-generalized-anxiety-symptom-severity 2026-06-09T17:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-uncovers-how-deadly-childhood-cancer-grows-highlights-two-potential-therapeutic-targets 2026-06-09T17:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-uncovers-how-deadly-childhood-cancer-grows-highlights-two-potential-therapeutic-targets 2026-06-09T17:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-ultrasound-professionals-launch-manifesto-demanding-end-to-recruitment-freezes-amid-diagnostic-workforce-crisis 2026-06-09T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-ultrasound-professionals-launch-manifesto-demanding-end-to-recruitment-freezes-amid-diagnostic-workforce-crisis 2026-06-09T17:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/australian-study-reveals-critical-gaps-in-black-triangle-scheme-awareness-for-medicine-safety-reporting 2026-06-09T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-study-reveals-critical-gaps-in-black-triangle-scheme-awareness-for-medicine-safety-reporting 2026-06-09T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/century-old-bcg-tuberculosis-vaccine-shows-promise-in-reducing-insulin-use-in-type-1-and-lada-diabetes 2026-06-09T17:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-old-bcg-tuberculosis-vaccine-shows-promise-in-reducing-insulin-use-in-type-1-and-lada-diabetes 2026-06-09T17:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/physician-scientist-couple-pursues-dual-doctorate-research-at-vcu-targeting-liver-cancer-and-chronic-skin-diseases 2026-06-09T17:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physician-scientist-couple-pursues-dual-doctorate-research-at-vcu-targeting-liver-cancer-and-chronic-skin-diseases 2026-06-09T17:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-scientists-discover-synthetic-lethality-between-rb-loss-and-e2f3-in-deadly-small-cell-cancers-opening-door-to-drug-repurposing 2026-06-09T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-scientists-discover-synthetic-lethality-between-rb-loss-and-e2f3-in-deadly-small-cell-cancers-opening-door-to-drug-repurposing 2026-06-09T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-announces-executive-leadership-transitions-robert-a-michael-to-assume-chairman-role-roopal-thakkar-named-r-d-chief 2026-06-09T17:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-announces-executive-leadership-transitions-robert-a-michael-to-assume-chairman-role-roopal-thakkar-named-r-d-chief 2026-06-09T17:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-foundation-awards-7-2m-to-12-young-investigators-for-high-risk-high-reward-research 2026-06-09T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckman-foundation-awards-7-2m-to-12-young-investigators-for-high-risk-high-reward-research 2026-06-09T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-associated-liver-disease-market-poised-for-31-1-cagr-growth-as-first-disease-modifying-therapies-near-approval 2026-06-09T17:38:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcohol-associated-liver-disease-market-poised-for-31-1-cagr-growth-as-first-disease-modifying-therapies-near-approval 2026-06-09T17:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/ai-screening-tool-increases-diabetic-eye-exam-referrals-for-african-americans-study-finds 2026-06-09T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-screening-tool-increases-diabetic-eye-exam-referrals-for-african-americans-study-finds 2026-06-09T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-launches-accelrare-an-ai-powered-pre-diagnosis-tool-for-rare-diseases-in-india 2026-06-09T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-launches-accelrare-an-ai-powered-pre-diagnosis-tool-for-rare-diseases-in-india 2026-06-09T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-q1-2026-revenue-hits-4-15-billion-as-r-d-solutions-and-commercial-analytics-drive-balanced-growth 2026-06-09T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-q1-2026-revenue-hits-4-15-billion-as-r-d-solutions-and-commercial-analytics-drive-balanced-growth 2026-06-09T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/agilus-diagnostics-launches-idylla-system-for-rapid-cancer-mutation-testing-in-under-3-hours 2026-06-09T16:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilus-diagnostics-launches-idylla-system-for-rapid-cancer-mutation-testing-in-under-3-hours 2026-06-09T16:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-the-buzzwords-a-surgeon-s-guide-to-12-commonly-misused-health-terms 2026-06-09T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-the-buzzwords-a-surgeon-s-guide-to-12-commonly-misused-health-terms 2026-06-09T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/spinafx-medical-receives-fda-ide-approval-for-triojection-pivotal-trial-in-contained-herniated-lumbar-discs 2026-06-09T16:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinafx-medical-receives-fda-ide-approval-for-triojection-pivotal-trial-in-contained-herniated-lumbar-discs 2026-06-09T16:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/closing-mexico-s-rare-disease-diagnostic-gap-a-strategic-imperative-for-healthcare-transformation 2026-06-09T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closing-mexico-s-rare-disease-diagnostic-gap-a-strategic-imperative-for-healthcare-transformation 2026-06-09T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/japanfold-launches-sovereign-open-source-drug-discovery-platform-running-entirely-inside-japan 2026-06-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanfold-launches-sovereign-open-source-drug-discovery-platform-running-entirely-inside-japan 2026-06-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-secures-fda-ind-clearance-and-fast-track-designation-for-atv-1601-in-hereditary-hemorrhagic-telangiectasia 2026-06-09T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atavistik-bio-secures-fda-ind-clearance-and-fast-track-designation-for-atv-1601-in-hereditary-hemorrhagic-telangiectasia 2026-06-09T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-research-foundation-and-astrazeneca-launch-750000-in-research-awards-targeting-small-cell-lung-cancer 2026-06-09T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-research-foundation-and-astrazeneca-launch-750000-in-research-awards-targeting-small-cell-lung-cancer 2026-06-09T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/rejuvenate-bio-closes-6-million-financing-partners-with-merck-animal-health-to-advance-gene-therapy-for-chronic-age-related-diseases-in-companion-animals 2026-06-09T15:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rejuvenate-bio-closes-6-million-financing-partners-with-merck-animal-health-to-advance-gene-therapy-for-chronic-age-related-diseases-in-companion-animals 2026-06-09T15:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/replacing-animal-protein-with-plant-protein-drives-weight-loss-in-postmenopausal-women-clinical-trial-shows 2026-06-09T15:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replacing-animal-protein-with-plant-protein-drives-weight-loss-in-postmenopausal-women-clinical-trial-shows 2026-06-09T15:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-doses-first-participant-in-phase-1-trial-of-cns-penetrant-tyk2-inhibitor-blkr201 2026-06-09T15:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formation-bio-doses-first-participant-in-phase-1-trial-of-cns-penetrant-tyk2-inhibitor-blkr201 2026-06-09T15:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/popular-joint-supplement-glucosamine-linked-to-faster-alzheimer-s-progression-in-large-retrospective-study 2026-06-09T15:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/popular-joint-supplement-glucosamine-linked-to-faster-alzheimer-s-progression-in-large-retrospective-study 2026-06-09T15:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/ub-launches-ub-hwi-bridge-initiative-to-integrate-structural-biology-ai-and-biomanufacturing 2026-06-09T15:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ub-launches-ub-hwi-bridge-initiative-to-integrate-structural-biology-ai-and-biomanufacturing 2026-06-09T15:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/resvita-bio-appoints-dermatology-expert-john-d-doux-to-board-as-topical-cell-therapy-platform-advances-toward-clinic 2026-06-09T15:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resvita-bio-appoints-dermatology-expert-john-d-doux-to-board-as-topical-cell-therapy-platform-advances-toward-clinic 2026-06-09T15:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/tga-warns-against-flumist-administration-in-children-under-2-following-over-100-adverse-event-reports 2026-06-09T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tga-warns-against-flumist-administration-in-children-under-2-following-over-100-adverse-event-reports 2026-06-09T15:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/ambient-ai-scribes-show-promise-in-reducing-physician-burnout-but-experts-urge-caution-on-privacy-accuracy-and-equity 2026-06-09T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambient-ai-scribes-show-promise-in-reducing-physician-burnout-but-experts-urge-caution-on-privacy-accuracy-and-equity 2026-06-09T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-sheba-medical-center-forge-strategic-partnership-to-accelerate-israeli-health-tech-innovation-globally 2026-06-09T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-sheba-medical-center-forge-strategic-partnership-to-accelerate-israeli-health-tech-innovation-globally 2026-06-09T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/matica-bio-and-vaxdome-partner-to-advance-antigen-agnostic-antiviral-vaccine-hybrid-into-clinical-trials 2026-06-09T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-bio-and-vaxdome-partner-to-advance-antigen-agnostic-antiviral-vaccine-hybrid-into-clinical-trials 2026-06-09T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/nord-appoints-kathryn-lowell-as-executive-vice-president-of-government-affairs-to-bridge-rare-disease-policy-and-innovation 2026-06-09T14:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nord-appoints-kathryn-lowell-as-executive-vice-president-of-government-affairs-to-bridge-rare-disease-policy-and-innovation 2026-06-09T14:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/ey-2026-biotech-beyond-borders-report-biotech-revenue-surges-13-to-232-billion-amid-financing-paradox-and-m-a-rebound 2026-06-09T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ey-2026-biotech-beyond-borders-report-biotech-revenue-surges-13-to-232-billion-amid-financing-paradox-and-m-a-rebound 2026-06-09T14:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/biocartis-and-city-of-hope-partner-to-develop-rapid-blood-based-gene-signature-test-for-early-pancreatic-cancer-detection 2026-06-09T13:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocartis-and-city-of-hope-partner-to-develop-rapid-blood-based-gene-signature-test-for-early-pancreatic-cancer-detection 2026-06-09T13:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/aifa-retrospective-analysis-reveals-added-therapeutic-value-as-key-driver-of-drug-innovativeness-recognition-in-oncology 2026-06-09T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aifa-retrospective-analysis-reveals-added-therapeutic-value-as-key-driver-of-drug-innovativeness-recognition-in-oncology 2026-06-09T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-to-showcase-ai-driven-small-molecule-discovery-platform-at-bio-2026 2026-06-09T13:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-to-showcase-ai-driven-small-molecule-discovery-platform-at-bio-2026 2026-06-09T13:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma 2026-06-09T12:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma 2026-06-09T12:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/lassarab-phase-1-trial-dual-lassa-rabies-vaccine-shows-100-seroconversion-and-favorable-safety-profile 2026-06-09T12:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lassarab-phase-1-trial-dual-lassa-rabies-vaccine-shows-100-seroconversion-and-favorable-safety-profile 2026-06-09T12:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-centers-turn-to-app-led-models-as-us-survivor-population-surpasses-19-million 2026-06-09T12:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-centers-turn-to-app-led-models-as-us-survivor-population-surpasses-19-million 2026-06-09T12:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-survivors-face-lingering-mental-health-crisis-as-survivorship-rates-climb 2026-06-09T12:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-survivors-face-lingering-mental-health-crisis-as-survivorship-rates-climb 2026-06-09T12:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-using-inactive-virus-safely-reduces-muscle-spasticity-after-chronic-spinal-cord-injury-in-preclinical-study 2026-06-09T12:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-using-inactive-virus-safely-reduces-muscle-spasticity-after-chronic-spinal-cord-injury-in-preclinical-study 2026-06-09T12:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/right-to-try-law-limited-use-no-evidence-for-thousands-of-lives-saved-claim 2026-06-09T12:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/right-to-try-law-limited-use-no-evidence-for-thousands-of-lives-saved-claim 2026-06-09T12:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/embedded-transparency-in-ai-a-prerequisite-for-equity-in-clinical-trials 2026-06-09T11:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embedded-transparency-in-ai-a-prerequisite-for-equity-in-clinical-trials 2026-06-09T11:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/measles-outbreak-in-utah-signals-looming-loss-of-us-elimination-status-as-vaccine-hesitancy-surges 2026-06-09T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-outbreak-in-utah-signals-looming-loss-of-us-elimination-status-as-vaccine-hesitancy-surges 2026-06-09T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-warns-omb-proposal-threatens-nih-s-lifesaving-cancer-research-mission 2026-06-09T10:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-warns-omb-proposal-threatens-nih-s-lifesaving-cancer-research-mission 2026-06-09T10:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/batten-1-advances-toward-pivotal-phase-3-trial-as-thx-pharma-biocodex-and-bbdf-unite-on-international-batten-disease-awareness-day 2026-06-09T10:12:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/batten-1-advances-toward-pivotal-phase-3-trial-as-thx-pharma-biocodex-and-bbdf-unite-on-international-batten-disease-awareness-day 2026-06-09T10:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/onconic-therapeutics-advances-global-expansion-of-gerd-drug-jakubo-with-mexico-nda-filing-and-u-s-manufacturing-partnership 2026-06-09T10:12:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconic-therapeutics-advances-global-expansion-of-gerd-drug-jakubo-with-mexico-nda-filing-and-u-s-manufacturing-partnership 2026-06-09T10:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/omani-researcher-s-novel-triazoline-compounds-show-broad-anticancer-and-antimicrobial-activity 2026-06-09T10:11:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omani-researcher-s-novel-triazoline-compounds-show-broad-anticancer-and-antimicrobial-activity 2026-06-09T10:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/new-health-risks-emerge-as-europe-s-drug-market-grows-more-complex-eu-agency-warns 2026-06-09T10:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-health-risks-emerge-as-europe-s-drug-market-grows-more-complex-eu-agency-warns 2026-06-09T10:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/philips-wins-fda-clearance-for-next-generation-pulse-oximeter-with-improved-accuracy-across-skin-tones 2026-06-09T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-wins-fda-clearance-for-next-generation-pulse-oximeter-with-improved-accuracy-across-skin-tones 2026-06-09T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-solutions-can-help-strengthen-rural-healthcare-operations 2026-06-09T08:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-solutions-can-help-strengthen-rural-healthcare-operations 2026-06-09T08:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/slamf6-identified-as-self-activating-t-cell-brake-behind-immunotherapy-resistance-new-monoclonal-antibodies-show-promise 2026-06-09T08:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/slamf6-identified-as-self-activating-t-cell-brake-behind-immunotherapy-resistance-new-monoclonal-antibodies-show-promise 2026-06-09T08:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/the-dynamic-genome-how-trillions-of-daily-mutations-shape-health-disease-and-the-future-of-gene-therapy 2026-06-09T08:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-dynamic-genome-how-trillions-of-daily-mutations-shape-health-disease-and-the-future-of-gene-therapy 2026-06-09T08:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/goldenrod-therapeutics-secures-6-5-million-seed-round-to-advance-cns-penetrant-pde4-inhibitor-toward-2027-clinical-trials 2026-06-09T08:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/goldenrod-therapeutics-secures-6-5-million-seed-round-to-advance-cns-penetrant-pde4-inhibitor-toward-2027-clinical-trials 2026-06-09T08:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/indaptus-therapeutics-halts-decoy20-development-pivots-to-strategic-review-after-12-million-financing 2026-06-09T08:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indaptus-therapeutics-halts-decoy20-development-pivots-to-strategic-review-after-12-million-financing 2026-06-09T08:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/artificial-intelligence-in-drug-discovery-a-critical-review-of-machine-and-deep-learning-applications-across-therapeutic-domains 2026-06-09T07:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artificial-intelligence-in-drug-discovery-a-critical-review-of-machine-and-deep-learning-applications-across-therapeutic-domains 2026-06-09T07:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/aprogen-advances-ap209-a-bispecific-receptor-osteoarthritis-drug-into-phase-1-clinical-trials-following-south-korean-ind-approval 2026-06-09T07:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprogen-advances-ap209-a-bispecific-receptor-osteoarthritis-drug-into-phase-1-clinical-trials-following-south-korean-ind-approval 2026-06-09T07:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/right-to-try-for-individualized-treatments-act-introduced-in-congress-to-expand-access-to-gene-therapies-for-rare-disease-patients 2026-06-09T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/right-to-try-for-individualized-treatments-act-introduced-in-congress-to-expand-access-to-gene-therapies-for-rare-disease-patients 2026-06-09T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/suzetrigine-a-novel-nav1-8-blocker-for-acute-pain-shows-promise-but-falls-short-of-opioid-superiority 2026-06-09T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suzetrigine-a-novel-nav1-8-blocker-for-acute-pain-shows-promise-but-falls-short-of-opioid-superiority 2026-06-09T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-secures-china-nmpa-approval-for-tivdak-first-adc-for-recurrent-or-metastatic-cervical-cancer 2026-06-09T06:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-secures-china-nmpa-approval-for-tivdak-first-adc-for-recurrent-or-metastatic-cervical-cancer 2026-06-09T06:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/menstrual-cycle-phase-linked-to-covid-19-vaccine-side-effects-and-breakthrough-infection-timing 2026-06-09T03:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menstrual-cycle-phase-linked-to-covid-19-vaccine-side-effects-and-breakthrough-infection-timing 2026-06-09T03:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-advances-novel-therapies-for-adolescent-and-young-adult-sarcomas 2026-06-09T02:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-advances-novel-therapies-for-adolescent-and-young-adult-sarcomas 2026-06-09T02:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-secures-u-s-patent-allowance-for-ibudilast-anti-pd-1-combination-in-glioblastoma 2026-06-09T01:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-secures-u-s-patent-allowance-for-ibudilast-anti-pd-1-combination-in-glioblastoma 2026-06-09T01:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/accelerated-biological-aging-may-explain-rising-early-onset-cancer-rates-study-suggests 2026-06-09T01:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerated-biological-aging-may-explain-rising-early-onset-cancer-rates-study-suggests 2026-06-09T01:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/optogenetic-brain-stimulation-reverses-sleep-deprivation-induced-memory-loss-in-mice 2026-06-09T00:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optogenetic-brain-stimulation-reverses-sleep-deprivation-induced-memory-loss-in-mice 2026-06-09T00:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-grants-ind-clearance-to-adcentrx-s-steap1-targeting-adc-adrx-0405-for-late-stage-solid-tumors 2026-06-09T00:37:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-grants-ind-clearance-to-adcentrx-s-steap1-targeting-adc-adrx-0405-for-late-stage-solid-tumors 2026-06-09T00:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-drug-conjugates-market-poised-to-reach-42-55-billion-by-2035-driven-by-adc-success-and-precision-medicine 2026-06-09T00:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-drug-conjugates-market-poised-to-reach-42-55-billion-by-2035-driven-by-adc-success-and-precision-medicine 2026-06-09T00:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-baxfendy-baxdrostat-a-novel-aldosterone-synthase-inhibitor-for-resistant-hypertension 2026-06-09T00:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-baxfendy-baxdrostat-a-novel-aldosterone-synthase-inhibitor-for-resistant-hypertension 2026-06-09T00:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/first-complete-fruit-fly-central-nervous-system-connectome-reveals-distributed-motor-control-architecture 2026-06-09T00:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-complete-fruit-fly-central-nervous-system-connectome-reveals-distributed-motor-control-architecture 2026-06-09T00:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-advances-anti-tslp-antibody-gb-0895-to-phase-iii-for-severe-asthma-plans-direct-phase-iii-in-copd 2026-06-09T00:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generate-biomedicines-advances-anti-tslp-antibody-gb-0895-to-phase-iii-for-severe-asthma-plans-direct-phase-iii-in-copd 2026-06-09T00:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/towards-the-construction-of-a-virtual-yeast-ai-driven-whole-cell-modeling-advances 2026-06-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/towards-the-construction-of-a-virtual-yeast-ai-driven-whole-cell-modeling-advances 2026-06-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-oral-glp-1-elecoglipron-achieves-11-8-weight-loss-in-phase-2-paving-way-for-pivotal-program 2026-06-08T22:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-oral-glp-1-elecoglipron-achieves-11-8-weight-loss-in-phase-2-paving-way-for-pivotal-program 2026-06-08T22:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/big-pharma-paychecks-revealed-gilead-leads-with-239000-median-salary-as-biotech-outpaces-traditional-drugmakers 2026-06-08T22:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/big-pharma-paychecks-revealed-gilead-leads-with-239000-median-salary-as-biotech-outpaces-traditional-drugmakers 2026-06-08T22:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-engitix-forge-strategic-collaboration-to-discover-first-in-class-targets-for-liver-fibrosis-regression 2026-06-08T21:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-engitix-forge-strategic-collaboration-to-discover-first-in-class-targets-for-liver-fibrosis-regression 2026-06-08T21:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-molecular-switch-uses-caffeine-to-control-engineered-cells 2026-06-08T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-molecular-switch-uses-caffeine-to-control-engineered-cells 2026-06-08T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-biopharma-shakti-initiative-targets-100-biologics-by-2047-to-become-global-biopharma-hub 2026-06-08T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-biopharma-shakti-initiative-targets-100-biologics-by-2047-to-become-global-biopharma-hub 2026-06-08T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-one-in-five-u-s-adults-unaware-diet-affects-blood-cholesterol-many-misinformed-about-meat-and-eggs 2026-06-08T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-one-in-five-u-s-adults-unaware-diet-affects-blood-cholesterol-many-misinformed-about-meat-and-eggs 2026-06-08T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-awards-nearly-7-million-in-build-our-future-grants-to-accelerate-biotech-medtech-and-life-sciences-innovation 2026-06-08T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-awards-nearly-7-million-in-build-our-future-grants-to-accelerate-biotech-medtech-and-life-sciences-innovation 2026-06-08T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-prices-upsized-600-million-public-offering-to-advance-precision-cancer-pipeline 2026-06-08T20:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tango-therapeutics-prices-upsized-600-million-public-offering-to-advance-precision-cancer-pipeline 2026-06-08T20:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-veteran-jeremy-levin-warns-u-s-leadership-in-drug-development-is-at-risk-amid-institutional-erosion 2026-06-08T20:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-veteran-jeremy-levin-warns-u-s-leadership-in-drug-development-is-at-risk-amid-institutional-erosion 2026-06-08T20:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tmem63b-biallelic-loss-of-function-variants-cause-severe-childhood-interstitial-lung-disease 2026-06-08T20:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tmem63b-biallelic-loss-of-function-variants-cause-severe-childhood-interstitial-lung-disease 2026-06-08T20:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-announces-major-expansion-of-nutrition-education-in-u-s-medical-schools 2026-06-08T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-announces-major-expansion-of-nutrition-education-in-u-s-medical-schools 2026-06-08T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/campbell-university-stem-programs-inspire-next-generation-of-pharmaceutical-researchers-and-healthcare-innovators 2026-06-08T19:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/campbell-university-stem-programs-inspire-next-generation-of-pharmaceutical-researchers-and-healthcare-innovators 2026-06-08T19:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-data-show-most-antibiotic-contaminated-shrimp-refusals-originate-from-bap-certified-facilities 2026-06-08T19:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-data-show-most-antibiotic-contaminated-shrimp-refusals-originate-from-bap-certified-facilities 2026-06-08T19:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/music-therapy-noninferior-to-cbt-for-anxiety-in-cancer-survivors-in-large-telehealth-trial 2026-06-08T19:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/music-therapy-noninferior-to-cbt-for-anxiety-in-cancer-survivors-in-large-telehealth-trial 2026-06-08T19:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/ukio-2026-ai-will-master-the-image-but-radiographers-must-master-the-patient-congress-president-declares 2026-06-08T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ukio-2026-ai-will-master-the-image-but-radiographers-must-master-the-patient-congress-president-declares 2026-06-08T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/failed-resolution-of-inflammation-in-intracerebral-haemorrhage-new-therapeutic-targets-emerge 2026-06-08T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/failed-resolution-of-inflammation-in-intracerebral-haemorrhage-new-therapeutic-targets-emerge 2026-06-08T19:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/consumer-reports-and-yuka-investigation-finds-1-in-4-popular-u-s-foods-exceed-daily-safety-levels-for-additives 2026-06-08T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consumer-reports-and-yuka-investigation-finds-1-in-4-popular-u-s-foods-exceed-daily-safety-levels-for-additives 2026-06-08T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/praeseed-programme-unveils-third-cohort-with-ps1-6m-funding-for-northern-england-s-deep-tech-and-life-sciences-startups 2026-06-08T17:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praeseed-programme-unveils-third-cohort-with-ps1-6m-funding-for-northern-england-s-deep-tech-and-life-sciences-startups 2026-06-08T17:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/chatgpt-outperforms-physicians-in-diagnostic-study-raising-questions-about-ai-s-role-in-medicine 2026-06-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chatgpt-outperforms-physicians-in-diagnostic-study-raising-questions-about-ai-s-role-in-medicine 2026-06-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-study-finds-health-insurance-coverage-gaps-limit-folic-acid-use-increasing-birth-defect-risks 2026-06-08T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-irvine-study-finds-health-insurance-coverage-gaps-limit-folic-acid-use-increasing-birth-defect-risks 2026-06-08T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/news/online-participant-engagement-portal-achieves-84-satisfaction-rate-in-national-cancer-clinical-trials 2026-06-08T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/online-participant-engagement-portal-achieves-84-satisfaction-rate-in-national-cancer-clinical-trials 2026-06-08T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-companion-diagnostic-market-to-reach-usd-14-65-billion-by-2035-driven-by-precision-oncology-expansion 2026-06-08T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-companion-diagnostic-market-to-reach-usd-14-65-billion-by-2035-driven-by-precision-oncology-expansion 2026-06-08T17:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/illinois-lawmakers-pass-dual-340b-bills-pharmacy-protections-and-transparency-audit-head-to-governor 2026-06-08T17:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illinois-lawmakers-pass-dual-340b-bills-pharmacy-protections-and-transparency-audit-head-to-governor 2026-06-08T17:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-reports-share-buy-back-progress-and-pdmr-transactions-amid-metabolic-health-pipeline-push 2026-06-08T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-reports-share-buy-back-progress-and-pdmr-transactions-amid-metabolic-health-pipeline-push 2026-06-08T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/standard-biotools-and-treeline-biosciences-announce-merger-creating-publicly-traded-oncology-focused-biopharma-with-over-900-million-in-cash 2026-06-08T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/standard-biotools-and-treeline-biosciences-announce-merger-creating-publicly-traded-oncology-focused-biopharma-with-over-900-million-in-cash 2026-06-08T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-cormedix-patent-victory-upholding-minocin-r-exclusivity-against-nexus-generic-challenge 2026-06-08T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-cormedix-patent-victory-upholding-minocin-r-exclusivity-against-nexus-generic-challenge 2026-06-08T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/the-fatal-flaw-in-pharma-s-multi-million-supply-chain-tech-upgrades-why-visibility-alone-cannot-build-resilience 2026-06-08T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-fatal-flaw-in-pharma-s-multi-million-supply-chain-tech-upgrades-why-visibility-alone-cannot-build-resilience 2026-06-08T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-subsidiary-acquires-international-nanotechnology-patent-expands-gmp-manufacturing-platform 2026-06-08T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-health-subsidiary-acquires-international-nanotechnology-patent-expands-gmp-manufacturing-platform 2026-06-08T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/liraglutide-combination-products-incorporating-stevanato-group-s-alina-r-pen-injector-receive-european-marketing-authorizations 2026-06-08T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liraglutide-combination-products-incorporating-stevanato-group-s-alina-r-pen-injector-receive-european-marketing-authorizations 2026-06-08T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ada-faces-leadership-crisis-after-police-eject-researchers-protesting-nih-cuts-at-annual-meeting 2026-06-08T16:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ada-faces-leadership-crisis-after-police-eject-researchers-protesting-nih-cuts-at-annual-meeting 2026-06-08T16:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-pharmaceuticals-to-acquire-colospan-creating-gi-focused-medtech-platform-targeting-6-billion-colorectal-surgery-market 2026-06-08T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-pharmaceuticals-to-acquire-colospan-creating-gi-focused-medtech-platform-targeting-6-billion-colorectal-surgery-market 2026-06-08T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/medera-expands-scientific-advisory-board-with-leading-heart-failure-and-cardiopulmonary-physiology-experts-to-advance-hfpef-gene-therapy-program 2026-06-08T16:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-expands-scientific-advisory-board-with-leading-heart-failure-and-cardiopulmonary-physiology-experts-to-advance-hfpef-gene-therapy-program 2026-06-08T16:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/ne-inbre-program-welcomes-new-cohort-of-undergraduate-biomedical-research-scholars-across-nebraska 2026-06-08T16:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ne-inbre-program-welcomes-new-cohort-of-undergraduate-biomedical-research-scholars-across-nebraska 2026-06-08T16:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-rna-oncology-pipeline-targeting-metastatic-cancer-with-novel-delivery-platform 2026-06-08T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-advances-rna-oncology-pipeline-targeting-metastatic-cancer-with-novel-delivery-platform 2026-06-08T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/waters-launches-industry-first-reversed-phase-bioseparation-columns-for-faster-glp-1-and-lnp-analysis 2026-06-08T16:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-launches-industry-first-reversed-phase-bioseparation-columns-for-faster-glp-1-and-lnp-analysis 2026-06-08T16:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/uab-and-musc-earn-top-tier-rankings-in-inaugural-cure-innovation-index-for-biomedical-translation 2026-06-08T15:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-and-musc-earn-top-tier-rankings-in-inaugural-cure-innovation-index-for-biomedical-translation 2026-06-08T15:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-authorizes-100-million-share-repurchase-program 2026-06-08T15:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-authorizes-100-million-share-repurchase-program 2026-06-08T15:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-stratamap-spatial-solution-delivering-whole-transcriptome-profiling-at-single-cell-resolution 2026-06-08T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-launches-stratamap-spatial-solution-delivering-whole-transcriptome-profiling-at-single-cell-resolution 2026-06-08T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-world-gene-therapy-delivers-wwox-gene-directly-to-infant-s-brain-for-rare-epilepsy-syndrome 2026-06-08T15:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-world-gene-therapy-delivers-wwox-gene-directly-to-infant-s-brain-for-rare-epilepsy-syndrome 2026-06-08T15:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-posts-record-h1-2026-revenue-as-keytruda-sc-sales-surge-262-and-platform-deals-expand 2026-06-08T15:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alteogen-posts-record-h1-2026-revenue-as-keytruda-sc-sales-surge-262-and-platform-deals-expand 2026-06-08T15:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/aso-targeting-zfp384-sustains-microglial-repair-activity-and-extends-stroke-recovery-window 2026-06-08T15:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aso-targeting-zfp384-sustains-microglial-repair-activity-and-extends-stroke-recovery-window 2026-06-08T15:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/ai-could-revolutionize-concussion-care-in-sport-but-validation-and-ethical-risks-remain 2026-06-08T15:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-could-revolutionize-concussion-care-in-sport-but-validation-and-ethical-risks-remain 2026-06-08T15:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/childhood-egg-allergies-decline-17-after-early-introduction-guidelines-landmark-study-shows 2026-06-08T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/childhood-egg-allergies-decline-17-after-early-introduction-guidelines-landmark-study-shows 2026-06-08T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-fluorescent-nanosensor-enables-rapid-first-of-its-kind-detection-of-gut-health-biomarker-ipa 2026-06-08T14:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-fluorescent-nanosensor-enables-rapid-first-of-its-kind-detection-of-gut-health-biomarker-ipa 2026-06-08T14:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-driven-multiomic-studies-reveal-novel-drug-targets-and-repurposing-opportunities-across-cardiovascular-psychiatric-and-autoimmune-diseases 2026-06-08T14:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-driven-multiomic-studies-reveal-novel-drug-targets-and-repurposing-opportunities-across-cardiovascular-psychiatric-and-autoimmune-diseases 2026-06-08T14:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-in-acute-heart-failure-early-initiation-after-stabilization-gains-guideline-support-though-key-questions-remain 2026-06-08T14:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-in-acute-heart-failure-early-initiation-after-stabilization-gains-guideline-support-though-key-questions-remain 2026-06-08T14:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/not-all-five-a-day-are-equal-study-reveals-most-people-miss-heart-protecting-flavanols-despite-following-dietary-guidelines 2026-06-08T14:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/not-all-five-a-day-are-equal-study-reveals-most-people-miss-heart-protecting-flavanols-despite-following-dietary-guidelines 2026-06-08T14:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-acquires-firefly-bio-in-1-billion-deal-to-advance-pan-kras-degrader-antibody-conjugates 2026-06-08T14:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-acquires-firefly-bio-in-1-billion-deal-to-advance-pan-kras-degrader-antibody-conjugates 2026-06-08T14:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/mri-before-biopsy-the-global-standard-prostate-cancer-diagnosis-the-u-s-has-yet-to-fully-embrace 2026-06-08T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mri-before-biopsy-the-global-standard-prostate-cancer-diagnosis-the-u-s-has-yet-to-fully-embrace 2026-06-08T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-market-projected-to-reach-456-81-billion-by-2035-driven-by-ai-diagnostics-and-national-genomics-programs 2026-06-08T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-market-projected-to-reach-456-81-billion-by-2035-driven-by-ai-diagnostics-and-national-genomics-programs 2026-06-08T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/sixteen-years-of-data-show-biopharma-r-d-returns-rebound-to-7-but-recovery-remains-concentrated-in-glp-1-therapies 2026-06-08T14:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sixteen-years-of-data-show-biopharma-r-d-returns-rebound-to-7-but-recovery-remains-concentrated-in-glp-1-therapies 2026-06-08T14:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/multidimensional-inflammatory-nutritional-risk-score-improves-post-transplant-prognostication-in-hcc 2026-06-08T14:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multidimensional-inflammatory-nutritional-risk-score-improves-post-transplant-prognostication-in-hcc 2026-06-08T14:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/zevra-therapeutics-extends-miplyffa-exclusivity-to-2041-with-fda-orange-book-patent-listing 2026-06-08T14:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zevra-therapeutics-extends-miplyffa-exclusivity-to-2041-with-fda-orange-book-patent-listing 2026-06-08T14:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-tumour-agnostic-immunotherapy-approvals-a-bold-policy-experiment-requiring-national-data-infrastructure 2026-06-08T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-tumour-agnostic-immunotherapy-approvals-a-bold-policy-experiment-requiring-national-data-infrastructure 2026-06-08T14:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-establishes-u-s-headquarters-and-manufacturing-facility-in-greater-boston-strengthens-executive-team-to-scale-lead-212-targeted-alpha-therapy-platform 2026-06-08T14:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-establishes-u-s-headquarters-and-manufacturing-facility-in-greater-boston-strengthens-executive-team-to-scale-lead-212-targeted-alpha-therapy-platform 2026-06-08T14:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/cervical-disc-replacement-at-20-years-benchmarking-revision-rates-and-refining-patient-selection 2026-06-08T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cervical-disc-replacement-at-20-years-benchmarking-revision-rates-and-refining-patient-selection 2026-06-08T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/eur15-3-million-act-chik-project-launches-to-advance-chikungunya-vaccine-clinical-trials-and-manufacturing-in-africa 2026-06-08T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eur15-3-million-act-chik-project-launches-to-advance-chikungunya-vaccine-clinical-trials-and-manufacturing-in-africa 2026-06-08T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/ai-unlocks-hidden-biomarkers-in-routine-ecgs-detecting-disease-and-predicting-mortality-beyond-human-capability 2026-06-08T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-unlocks-hidden-biomarkers-in-routine-ecgs-detecting-disease-and-predicting-mortality-beyond-human-capability 2026-06-08T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-appoints-new-heads-of-discovery-solutions-and-strategy-business-development 2026-06-08T12:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milliporesigma-appoints-new-heads-of-discovery-solutions-and-strategy-business-development 2026-06-08T12:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaxart-board-battle-intensifies-as-independent-directors-urge-shareholders-to-back-all-six-nominees-ahead-of-july-16-annual-meeting 2026-06-08T12:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxart-board-battle-intensifies-as-independent-directors-urge-shareholders-to-back-all-six-nominees-ahead-of-july-16-annual-meeting 2026-06-08T12:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-acquire-vega-therapeutics-for-up-to-2-billion-adding-phase-3-monoclonal-antibody-for-von-willebrand-disease 2026-06-08T12:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-to-acquire-vega-therapeutics-for-up-to-2-billion-adding-phase-3-monoclonal-antibody-for-von-willebrand-disease 2026-06-08T12:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-cd19-bcma-car-t-cell-therapy-demonstrates-profound-remission-in-refractory-systemic-sclerosis 2026-06-08T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-cd19-bcma-car-t-cell-therapy-demonstrates-profound-remission-in-refractory-systemic-sclerosis 2026-06-08T12:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/persongen-biotherapeutics-wins-2026-forbes-china-industry-leading-enterprise-award-for-breakthrough-car-t-innovation 2026-06-08T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persongen-biotherapeutics-wins-2026-forbes-china-industry-leading-enterprise-award-for-breakthrough-car-t-innovation 2026-06-08T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-secures-cms-ntap-reimbursement-for-first-fda-cleared-point-of-care-delirium-monitor 2026-06-08T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceribell-secures-cms-ntap-reimbursement-for-first-fda-cleared-point-of-care-delirium-monitor 2026-06-08T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-s-oral-aldh2-activator-mirivadelgat-selected-for-parkinson-s-disease-platform-trial 2026-06-08T11:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-s-oral-aldh2-activator-mirivadelgat-selected-for-parkinson-s-disease-platform-trial 2026-06-08T11:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-therapeutics-appoints-johan-liwing-as-new-ceo-to-advance-cell-and-gene-therapy-pipeline 2026-06-08T11:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicera-therapeutics-appoints-johan-liwing-as-new-ceo-to-advance-cell-and-gene-therapy-pipeline 2026-06-08T11:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-stress-drives-nk-cell-exhaustion-in-cold-tumors-via-gdf15-ahr-axis 2026-06-08T11:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-stress-drives-nk-cell-exhaustion-in-cold-tumors-via-gdf15-ahr-axis 2026-06-08T11:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-warning-letter-to-genzyme-ireland-raises-supply-chain-alarm-for-altuviiio-clinical-trials 2026-06-08T11:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-warning-letter-to-genzyme-ireland-raises-supply-chain-alarm-for-altuviiio-clinical-trials 2026-06-08T11:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-reduces-remimazolam-ed50-by-26-in-pediatric-procedural-sedation-study-finds 2026-06-08T11:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obesity-reduces-remimazolam-ed50-by-26-in-pediatric-procedural-sedation-study-finds 2026-06-08T11:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-vaccine-for-pancreatic-cancer-enters-phase-iii-trials-china-leads-global-race 2026-06-08T11:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-mrna-vaccine-for-pancreatic-cancer-enters-phase-iii-trials-china-leads-global-race 2026-06-08T11:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-single-patient-record-trust-will-determine-success-of-landmark-digital-health-reform-warns-nhs-alliance-chief 2026-06-08T11:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-single-patient-record-trust-will-determine-success-of-landmark-digital-health-reform-warns-nhs-alliance-chief 2026-06-08T11:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/unanswered-questions-loom-over-gender-affirming-hormone-therapy-for-transgender-patients-with-ibd 2026-06-08T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unanswered-questions-loom-over-gender-affirming-hormone-therapy-for-transgender-patients-with-ibd 2026-06-08T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/labvantage-launches-cortex-an-agentic-ai-platform-that-transforms-lims-from-passive-data-repositories-to-autonomous-laboratory-orchestrators 2026-06-08T10:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labvantage-launches-cortex-an-agentic-ai-platform-that-transforms-lims-from-passive-data-repositories-to-autonomous-laboratory-orchestrators 2026-06-08T10:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/jak-stat1-med15-axis-drives-melanocyte-dysfunction-in-vitiligo-study-reveals 2026-06-08T10:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-stat1-med15-axis-drives-melanocyte-dysfunction-in-vitiligo-study-reveals 2026-06-08T10:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/innovation-alone-is-no-longer-enough-how-operational-readiness-is-reshaping-biopharma-competitive-advantage 2026-06-08T10:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovation-alone-is-no-longer-enough-how-operational-readiness-is-reshaping-biopharma-competitive-advantage 2026-06-08T10:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-guided-immunosuppression-shows-safety-in-kidney-transplant-ttvguideit-phase-ii-trial-meets-primary-endpoint 2026-06-08T10:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-guided-immunosuppression-shows-safety-in-kidney-transplant-ttvguideit-phase-ii-trial-meets-primary-endpoint 2026-06-08T10:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/roche-enters-2-3-billion-cancer-drug-deal-with-nurix-therapeutics-for-blood-cancer-therapy-bexobrutideg 2026-06-08T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-enters-2-3-billion-cancer-drug-deal-with-nurix-therapeutics-for-blood-cancer-therapy-bexobrutideg 2026-06-08T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/combinatorial-in-situ-cancer-vaccines-unlocking-broad-and-enhanced-antitumor-responses 2026-06-08T10:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combinatorial-in-situ-cancer-vaccines-unlocking-broad-and-enhanced-antitumor-responses 2026-06-08T10:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/celecoxib-loaded-nano-in-nano-hierarchical-implant-shows-dual-drug-delivery-and-mechanical-support-for-osteoarthritis 2026-06-08T10:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celecoxib-loaded-nano-in-nano-hierarchical-implant-shows-dual-drug-delivery-and-mechanical-support-for-osteoarthritis 2026-06-08T10:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/curasight-reports-encouraging-phase-1-data-for-utreat-r-in-glioblastoma-supporting-continued-development 2026-06-08T10:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curasight-reports-encouraging-phase-1-data-for-utreat-r-in-glioblastoma-supporting-continued-development 2026-06-08T10:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-tool-predicts-meningioma-recurrence-from-routine-pathology-slides-with-97-accuracy 2026-06-08T10:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-tool-predicts-meningioma-recurrence-from-routine-pathology-slides-with-97-accuracy 2026-06-08T10:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/eortc-1537-cobra-very-early-pet-guided-therapy-switch-achieves-89-5-2-year-mpfs-in-advanced-stage-hodgkin-lymphoma 2026-06-08T10:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eortc-1537-cobra-very-early-pet-guided-therapy-switch-achieves-89-5-2-year-mpfs-in-advanced-stage-hodgkin-lymphoma 2026-06-08T10:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/financial-infrastructure-lacks-capacity-for-2-million-gene-therapies-health-economist-warns 2026-06-08T10:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/financial-infrastructure-lacks-capacity-for-2-million-gene-therapies-health-economist-warns 2026-06-08T10:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/hidden-high-beta-brain-rhythm-pinpoints-how-deep-brain-stimulation-relieves-parkinson-s-symptoms 2026-06-08T09:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hidden-high-beta-brain-rhythm-pinpoints-how-deep-brain-stimulation-relieves-parkinson-s-symptoms 2026-06-08T09:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogene-therapeutics-appoints-ty-howton-veteran-biopharma-executive-to-board-of-directors 2026-06-08T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogene-therapeutics-appoints-ty-howton-veteran-biopharma-executive-to-board-of-directors 2026-06-08T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/promomed-to-invest-1-4-billion-roubles-in-small-batch-production-of-rare-disease-drugs 2026-06-08T09:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promomed-to-invest-1-4-billion-roubles-in-small-batch-production-of-rare-disease-drugs 2026-06-08T09:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-calls-on-g7-to-make-innovation-a-strategic-economic-priority-ahead-of-evian-summit 2026-06-08T09:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-calls-on-g7-to-make-innovation-a-strategic-economic-priority-ahead-of-evian-summit 2026-06-08T09:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/the-road-to-commercial-scale-ipsc-cell-therapy-overcoming-manufacturing-bottlenecks-for-off-the-shelf-therapies 2026-06-08T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-road-to-commercial-scale-ipsc-cell-therapy-overcoming-manufacturing-bottlenecks-for-off-the-shelf-therapies 2026-06-08T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/hospital-authority-launches-office-to-fast-track-innovative-drug-approvals-in-hong-kong-cutting-review-times-by-one-third 2026-06-08T08:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hospital-authority-launches-office-to-fast-track-innovative-drug-approvals-in-hong-kong-cutting-review-times-by-one-third 2026-06-08T08:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/bruker-unveils-expanded-maldi-biotyper-library-and-rapid-sepsis-ast-workflow-at-asm-microbe-2026 2026-06-08T07:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruker-unveils-expanded-maldi-biotyper-library-and-rapid-sepsis-ast-workflow-at-asm-microbe-2026 2026-06-08T07:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-second-reinvention-beyond-oncology-into-obesity-ibd-and-cell-therapy 2026-06-08T06:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-second-reinvention-beyond-oncology-into-obesity-ibd-and-cell-therapy 2026-06-08T06:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/structure-guided-identification-of-a-potential-small-molecule-inhibitor-targeting-the-vaca-toxin-of-helicobacter-pylori 2026-06-08T06:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-guided-identification-of-a-potential-small-molecule-inhibitor-targeting-the-vaca-toxin-of-helicobacter-pylori 2026-06-08T06:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/gni-group-to-acquire-ayumi-pharmaceutical-for-y-44-8-billion-building-a-cross-pacific-biopharmaceutical-platform 2026-06-08T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gni-group-to-acquire-ayumi-pharmaceutical-for-y-44-8-billion-building-a-cross-pacific-biopharmaceutical-platform 2026-06-08T05:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-phase-1-trial-of-adcx-020-for-advanced-solid-tumors-launches-at-sunshine-coast-hospital 2026-06-08T05:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-phase-1-trial-of-adcx-020-for-advanced-solid-tumors-launches-at-sunshine-coast-hospital 2026-06-08T05:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/philanthropic-surge-reshapes-south-florida-s-healthcare-and-research-landscape 2026-06-08T04:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philanthropic-surge-reshapes-south-florida-s-healthcare-and-research-landscape 2026-06-08T04:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-application-of-histone-deacetylase-inhibitors-for-central-nervous-system-disorders 2026-06-08T04:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-application-of-histone-deacetylase-inhibitors-for-central-nervous-system-disorders 2026-06-08T04:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-shows-unexpected-cognitive-improvements-in-advanced-alzheimer-s-case-report 2026-06-08T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-shows-unexpected-cognitive-improvements-in-advanced-alzheimer-s-case-report 2026-06-08T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-ceo-albert-bourla-outlines-strategy-to-catch-up-in-obesity-and-cancer-drug-development 2026-06-08T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-ceo-albert-bourla-outlines-strategy-to-catch-up-in-obesity-and-cancer-drug-development 2026-06-08T01:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/the-good-bad-and-ugly-in-healthcare-all-in-one-week 2026-06-08T00:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-good-bad-and-ugly-in-healthcare-all-in-one-week 2026-06-08T00:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-apnea-s-hidden-heart-disease-trigger-found-in-the-gut-fxr-receptor-drives-atherosclerosis 2026-06-08T00:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-apnea-s-hidden-heart-disease-trigger-found-in-the-gut-fxr-receptor-drives-atherosclerosis 2026-06-08T00:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-dots-in-biomedicine-from-precision-imaging-to-single-virus-tracking-and-the-road-to-clinical-translation 2026-06-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-dots-in-biomedicine-from-precision-imaging-to-single-virus-tracking-and-the-road-to-clinical-translation 2026-06-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/discovery-of-arr-x-a-novel-highly-efficient-rifamycin-inactivating-enzyme-family-reveals-new-antibiotic-resistance-mechanisms-across-mycobacteria 2026-06-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/discovery-of-arr-x-a-novel-highly-efficient-rifamycin-inactivating-enzyme-family-reveals-new-antibiotic-resistance-mechanisms-across-mycobacteria 2026-06-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/switching-to-a-healthy-diet-may-partially-reverse-memory-damage-from-high-fat-high-sugar-foods-but-sugar-s-effects-may-linger 2026-06-07T23:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/switching-to-a-healthy-diet-may-partially-reverse-memory-damage-from-high-fat-high-sugar-foods-but-sugar-s-effects-may-linger 2026-06-07T23:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/daily-probiotic-shows-modest-benefit-for-depression-and-anxiety-in-seniors-pilot-trial 2026-06-07T23:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-probiotic-shows-modest-benefit-for-depression-and-anxiety-in-seniors-pilot-trial 2026-06-07T23:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/thymic-radiation-dose-may-influence-distant-metastasis-risk-in-locally-advanced-nsclc 2026-06-07T22:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thymic-radiation-dose-may-influence-distant-metastasis-risk-in-locally-advanced-nsclc 2026-06-07T22:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/female-sex-linked-to-superior-outcomes-in-cd19-directed-car-t-cell-therapy-for-large-b-cell-lymphoma 2026-06-07T22:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/female-sex-linked-to-superior-outcomes-in-cd19-directed-car-t-cell-therapy-for-large-b-cell-lymphoma 2026-06-07T22:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/how-a-gut-bacterium-rewires-colon-cells-to-fuel-colitis-and-colorectal-cancer 2026-06-07T22:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-a-gut-bacterium-rewires-colon-cells-to-fuel-colitis-and-colorectal-cancer 2026-06-07T22:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-completes-phase-3-trials-with-70-efficacy 2026-06-07T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-completes-phase-3-trials-with-70-efficacy 2026-06-07T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/head-to-head-study-validates-clinical-advantage-of-camp-biased-glp-1-agonist-ecnoglutide-35-greater-weight-loss-than-semaglutide-at-week-20 2026-06-07T20:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/head-to-head-study-validates-clinical-advantage-of-camp-biased-glp-1-agonist-ecnoglutide-35-greater-weight-loss-than-semaglutide-at-week-20 2026-06-07T20:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/wolfe-research-initiates-west-pharmaceutical-services-at-outperform-citing-glp-1-growth-and-injectable-drug-market-tailwinds 2026-06-07T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wolfe-research-initiates-west-pharmaceutical-services-at-outperform-citing-glp-1-growth-and-injectable-drug-market-tailwinds 2026-06-07T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-foundation-launches-eur60-million-cardiometabolic-bridge-to-accelerate-drug-discovery-across-europe 2026-06-07T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-foundation-launches-eur60-million-cardiometabolic-bridge-to-accelerate-drug-discovery-across-europe 2026-06-07T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/asco-2026-redefines-cancer-survivorship-from-survival-to-living-well-across-the-entire-cancer-journey 2026-06-07T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-2026-redefines-cancer-survivorship-from-survival-to-living-well-across-the-entire-cancer-journey 2026-06-07T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/stop-games-act-targeting-fda-citizen-petitions-draws-sharp-criticism-from-former-fda-official 2026-06-07T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stop-games-act-targeting-fda-citizen-petitions-draws-sharp-criticism-from-former-fda-official 2026-06-07T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-therapeutics-poised-to-redefine-drug-discovery-and-precision-medicine-says-leucine-rich-bio-co-founder 2026-06-07T19:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiome-therapeutics-poised-to-redefine-drug-discovery-and-precision-medicine-says-leucine-rich-bio-co-founder 2026-06-07T19:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-reshapes-brain-tumour-care-survival-improves-as-molecular-diagnostics-and-targeted-therapies-advance 2026-06-07T19:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-reshapes-brain-tumour-care-survival-improves-as-molecular-diagnostics-and-targeted-therapies-advance 2026-06-07T19:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-pharma-giants-pour-27-billion-into-u-s-operations-following-tariff-agreement 2026-06-07T19:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-pharma-giants-pour-27-billion-into-u-s-operations-following-tariff-agreement 2026-06-07T19:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/vunakizumab-shows-sustained-efficacy-in-radiographic-axial-spondyloarthritis-jama 2026-06-07T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vunakizumab-shows-sustained-efficacy-in-radiographic-axial-spondyloarthritis-jama 2026-06-07T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/israel-monitors-suspected-ebola-case-as-bundibugyo-outbreak-spreads-across-central-africa 2026-06-07T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israel-monitors-suspected-ebola-case-as-bundibugyo-outbreak-spreads-across-central-africa 2026-06-07T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/institutional-investors-reshape-illumina-holdings-as-norges-bank-and-capital-world-investors-boost-stakes 2026-06-07T16:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/institutional-investors-reshape-illumina-holdings-as-norges-bank-and-capital-world-investors-boost-stakes 2026-06-07T16:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/new-acip-charter-broadens-criteria-refocuses-mission-amid-legal-and-public-health-uncertainty 2026-06-07T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-acip-charter-broadens-criteria-refocuses-mission-amid-legal-and-public-health-uncertainty 2026-06-07T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/ada-2026-pharmacist-ce-programs-may-reduce-clinical-inertia-in-type-2-diabetes 2026-06-07T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ada-2026-pharmacist-ce-programs-may-reduce-clinical-inertia-in-type-2-diabetes 2026-06-07T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/professor-richard-scolyer-melanoma-pioneer-who-turned-his-glioblastoma-into-a-landmark-immunotherapy-experiment-dies-at-59 2026-06-07T16:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/professor-richard-scolyer-melanoma-pioneer-who-turned-his-glioblastoma-into-a-landmark-immunotherapy-experiment-dies-at-59 2026-06-07T16:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-hospitals-adopt-non-invasive-galeas-bladder-test-a-faster-and-more-accurate-alternative-to-cystoscopy 2026-06-07T16:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-hospitals-adopt-non-invasive-galeas-bladder-test-a-faster-and-more-accurate-alternative-to-cystoscopy 2026-06-07T16:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/mizuho-strategist-reframes-healthcare-as-a-value-sector-amid-pharma-underperformance-highlights-merck-s-keytruda-dominance 2026-06-07T15:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mizuho-strategist-reframes-healthcare-as-a-value-sector-amid-pharma-underperformance-highlights-merck-s-keytruda-dominance 2026-06-07T15:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/us-japan-forge-1-billion-tech-alliance-targeting-ai-quantum-computing-fusion-energy-and-biotechnology 2026-06-07T15:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-japan-forge-1-billion-tech-alliance-targeting-ai-quantum-computing-fusion-energy-and-biotechnology 2026-06-07T15:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/dipika-kakar-initiates-immunotherapy-for-stage-2-liver-cancer-as-family-clarifies-no-further-surgery-planned 2026-06-07T13:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dipika-kakar-initiates-immunotherapy-for-stage-2-liver-cancer-as-family-clarifies-no-further-surgery-planned 2026-06-07T13:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/aimwellbio-launches-public-ai-signal-feed-challenging-biopharma-intelligence-industry-to-verify-before-trusting 2026-06-07T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aimwellbio-launches-public-ai-signal-feed-challenging-biopharma-intelligence-industry-to-verify-before-trusting 2026-06-07T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/curcumin-preserves-aortic-structure-and-function-in-type-1-diabetes-rat-study-finds 2026-06-07T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curcumin-preserves-aortic-structure-and-function-in-type-1-diabetes-rat-study-finds 2026-06-07T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/lymph-node-structural-changes-may-predict-breast-cancer-spread-offering-path-to-personalized-treatment 2026-06-07T12:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lymph-node-structural-changes-may-predict-breast-cancer-spread-offering-path-to-personalized-treatment 2026-06-07T12:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/bonecot-a-whole-body-skeleton-foundation-model-validated-for-bone-metastasis-detection-across-multiple-centres 2026-06-07T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bonecot-a-whole-body-skeleton-foundation-model-validated-for-bone-metastasis-detection-across-multiple-centres 2026-06-07T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/ancient-chinese-root-polygonum-multiflorum-shows-multi-target-potential-against-androgenetic-alopecia 2026-06-07T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ancient-chinese-root-polygonum-multiflorum-shows-multi-target-potential-against-androgenetic-alopecia 2026-06-07T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-supplementation-in-pregnancy-does-not-prevent-preterm-birth-meta-analysis-finds 2026-06-07T11:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitamin-d-supplementation-in-pregnancy-does-not-prevent-preterm-birth-meta-analysis-finds 2026-06-07T11:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/vibrio-vulnificus-expands-northward-along-u-s-atlantic-coast-as-climate-change-fuels-spread-researchers-race-to-build-early-warning-system 2026-06-07T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vibrio-vulnificus-expands-northward-along-u-s-atlantic-coast-as-climate-change-fuels-spread-researchers-race-to-build-early-warning-system 2026-06-07T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-draws-strong-institutional-interest-as-analysts-maintain-bullish-outlook 2026-06-07T11:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edwards-lifesciences-draws-strong-institutional-interest-as-analysts-maintain-bullish-outlook 2026-06-07T11:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/process-analytical-technology-reshapes-pharma-manufacturing-from-end-product-testing-to-real-time-quality-assurance 2026-06-07T10:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/process-analytical-technology-reshapes-pharma-manufacturing-from-end-product-testing-to-real-time-quality-assurance 2026-06-07T10:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/how-ai-powered-drug-discovery-is-accelerating-breakthroughs-across-oncology-cardiology-and-metabolic-disease 2026-06-07T07:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-ai-powered-drug-discovery-is-accelerating-breakthroughs-across-oncology-cardiology-and-metabolic-disease 2026-06-07T07:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/ai-medical-reference-tools-face-accuracy-scrutiny-as-physician-adoption-surges 2026-06-07T07:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-medical-reference-tools-face-accuracy-scrutiny-as-physician-adoption-surges 2026-06-07T07:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/health-security-intelligence-operations-center-launches-at-georgetown-university-to-track-world-cup-disease-risks 2026-06-07T06:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-security-intelligence-operations-center-launches-at-georgetown-university-to-track-world-cup-disease-risks 2026-06-07T06:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-and-turtletree-partner-to-scale-precision-fermented-lactoferrin-for-global-nutrition-markets 2026-06-07T05:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novonesis-and-turtletree-partner-to-scale-precision-fermented-lactoferrin-for-global-nutrition-markets 2026-06-07T05:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/xrhealth-acquires-swing-therapeutics-to-expand-digital-therapeutics-portfolio 2026-06-07T05:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xrhealth-acquires-swing-therapeutics-to-expand-digital-therapeutics-portfolio 2026-06-07T05:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/the-gut-brain-axis-in-ibd-anxiety-depression-comorbidity-a-network-of-four-interconnected-inflammatory-pathways 2026-06-07T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-gut-brain-axis-in-ibd-anxiety-depression-comorbidity-a-network-of-four-interconnected-inflammatory-pathways 2026-06-07T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/alcohol-may-trick-the-brain-into-craving-junk-food-via-the-hormone-fgf21-study-suggests 2026-06-07T04:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcohol-may-trick-the-brain-into-craving-junk-food-via-the-hormone-fgf21-study-suggests 2026-06-07T04:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-appoints-dr-lynn-seely-former-myovant-ceo-and-xtandi-development-lead-to-board-of-directors 2026-06-07T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcellera-appoints-dr-lynn-seely-former-myovant-ceo-and-xtandi-development-lead-to-board-of-directors 2026-06-07T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/as-adolescent-overdoses-rise-states-move-to-put-naloxone-in-schools 2026-06-07T03:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/as-adolescent-overdoses-rise-states-move-to-put-naloxone-in-schools 2026-06-07T03:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/leo-cancer-care-raises-65m-series-d-following-world-first-upright-proton-therapy-treatment-at-stanford-medicine 2026-06-07T03:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-cancer-care-raises-65m-series-d-following-world-first-upright-proton-therapy-treatment-at-stanford-medicine 2026-06-07T03:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/allergy-action-ireland-urges-national-rollout-of-oral-immunotherapy-following-success-at-cork-university-hospital 2026-06-07T02:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergy-action-ireland-urges-national-rollout-of-oral-immunotherapy-following-success-at-cork-university-hospital 2026-06-07T02:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/saliva-based-surrogate-marker-predicts-malignant-transformation-in-oral-potentially-malignant-disorders 2026-06-07T02:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saliva-based-surrogate-marker-predicts-malignant-transformation-in-oral-potentially-malignant-disorders 2026-06-07T02:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/mayim-bialik-details-severe-adverse-reaction-to-glp-1-medication-prescribed-for-autoimmune-inflammation 2026-06-07T02:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayim-bialik-details-severe-adverse-reaction-to-glp-1-medication-prescribed-for-autoimmune-inflammation 2026-06-07T02:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-vs-dexcom-which-diabetes-technology-stock-offers-better-value-in-2026 2026-06-07T00:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulet-vs-dexcom-which-diabetes-technology-stock-offers-better-value-in-2026 2026-06-07T00:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/phytic-acid-in-plant-foods-activates-hdac3-to-strengthen-gut-barrier-preclinical-study-finds 2026-06-07T00:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phytic-acid-in-plant-foods-activates-hdac3-to-strengthen-gut-barrier-preclinical-study-finds 2026-06-07T00:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/study-challenges-assumption-that-summer-sun-restores-vitamin-d-levels-in-high-risk-groups 2026-06-06T23:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-challenges-assumption-that-summer-sun-restores-vitamin-d-levels-in-high-risk-groups 2026-06-06T23:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-pipeline-driven-resilience-darzalex-carvykti-and-tremfya-fuel-10-revenue-growth-amid-stelara-patent-cliff 2026-06-06T23:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-pipeline-driven-resilience-darzalex-carvykti-and-tremfya-fuel-10-revenue-growth-amid-stelara-patent-cliff 2026-06-06T23:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/distinct-epigenetic-signatures-reveal-how-aging-and-type-2-diabetes-differently-reshape-pancreatic-islets 2026-06-06T22:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distinct-epigenetic-signatures-reveal-how-aging-and-type-2-diabetes-differently-reshape-pancreatic-islets 2026-06-06T22:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/serena-williams-comeback-ignites-debate-on-glp-1s-and-performance-enhancement-in-elite-sports 2026-06-06T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serena-williams-comeback-ignites-debate-on-glp-1s-and-performance-enhancement-in-elite-sports 2026-06-06T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-torch-surveillance-reveals-persistent-congenital-infection-risks-in-north-india-despite-vaccination-gains 2026-06-06T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-torch-surveillance-reveals-persistent-congenital-infection-risks-in-north-india-despite-vaccination-gains 2026-06-06T22:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-06T22:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference 2026-06-06T22:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/advocacy-groups-push-back-against-virginia-s-proposed-900-increase-in-public-cannabis-use-fines 2026-06-06T22:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advocacy-groups-push-back-against-virginia-s-proposed-900-increase-in-public-cannabis-use-fines 2026-06-06T22:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/eight-common-food-preservatives-linked-to-hypertension-and-cardiovascular-risk-in-large-french-cohort-study 2026-06-06T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-common-food-preservatives-linked-to-hypertension-and-cardiovascular-risk-in-large-french-cohort-study 2026-06-06T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/single-fraction-sbrt-shows-promise-in-localized-prostate-cancer-meeting-primary-endpoint-in-phase-1-2-trial 2026-06-06T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-fraction-sbrt-shows-promise-in-localized-prostate-cancer-meeting-primary-endpoint-in-phase-1-2-trial 2026-06-06T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-s-clym116-demonstrates-clean-phase-1-safety-profile-advancing-toward-igan-patient-studies-in-2026 2026-06-06T20:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climb-bio-s-clym116-demonstrates-clean-phase-1-safety-profile-advancing-toward-igan-patient-studies-in-2026 2026-06-06T20:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-mammography-expands-beyond-cancer-detection-to-predict-cardiovascular-risk 2026-06-06T19:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-mammography-expands-beyond-cancer-detection-to-predict-cardiovascular-risk 2026-06-06T19:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/pre-travel-health-planning-essential-as-summer-travel-surges-experts-warn 2026-06-06T19:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-travel-health-planning-essential-as-summer-travel-surges-experts-warn 2026-06-06T19:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/biomarkers-and-precision-oncology-forum-2026-to-feature-agnostic-molecular-tumor-board-and-leading-experts-in-singapore 2026-06-06T19:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarkers-and-precision-oncology-forum-2026-to-feature-agnostic-molecular-tumor-board-and-leading-experts-in-singapore 2026-06-06T19:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-houston-launches-uh-health-a-cross-disciplinary-academic-health-enterprise-to-address-texas-healthcare-challenges 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-houston-launches-uh-health-a-cross-disciplinary-academic-health-enterprise-to-address-texas-healthcare-challenges 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-demonstrates-86-overall-remission-in-refractory-membranous-nephropathy-first-single-arm-meta-analysis 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obinutuzumab-demonstrates-86-overall-remission-in-refractory-membranous-nephropathy-first-single-arm-meta-analysis 2026-06-06T19:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-medicare-vs-medicare-advantage-how-seniors-can-choose-the-plan-that-still-works-when-health-needs-change 2026-06-06T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-medicare-vs-medicare-advantage-how-seniors-can-choose-the-plan-that-still-works-when-health-needs-change 2026-06-06T19:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/msk-kids-expands-pediatric-cellular-therapy-program-under-leadership-of-dr-kevin-curran 2026-06-06T18:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msk-kids-expands-pediatric-cellular-therapy-program-under-leadership-of-dr-kevin-curran 2026-06-06T18:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/alliance-clinical-network-and-atlas-clinical-research-merge-to-form-national-clinical-trial-platform 2026-06-06T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alliance-clinical-network-and-atlas-clinical-research-merge-to-form-national-clinical-trial-platform 2026-06-06T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/eclinical-solutions-market-to-reach-40-7-billion-by-2034-driven-by-ai-decentralized-trials-and-cloud-adoption 2026-06-06T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eclinical-solutions-market-to-reach-40-7-billion-by-2034-driven-by-ai-decentralized-trials-and-cloud-adoption 2026-06-06T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/newer-glp-1s-pushback-on-research-cuts-and-a-protest-at-ada-2026 2026-06-06T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newer-glp-1s-pushback-on-research-cuts-and-a-protest-at-ada-2026 2026-06-06T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-trial-access-significantly-lower-for-people-living-with-hiv-study-finds 2026-06-06T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-trial-access-significantly-lower-for-people-living-with-hiv-study-finds 2026-06-06T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-protein-degradation-the-next-frontier-in-drugging-the-undruggable 2026-06-06T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-protein-degradation-the-next-frontier-in-drugging-the-undruggable 2026-06-06T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-blood-test-accurately-classifies-multiple-neurodegenerative-diseases-and-detects-co-existing-conditions 2026-06-06T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-blood-test-accurately-classifies-multiple-neurodegenerative-diseases-and-detects-co-existing-conditions 2026-06-06T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/pcn-seals-572-medicine-outlets-in-plateau-state-over-widespread-regulatory-violations 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcn-seals-572-medicine-outlets-in-plateau-state-over-widespread-regulatory-violations 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-reports-record-q2-2026-revenue-raises-full-year-guidance-on-surging-eversense-cgm-demand 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-reports-record-q2-2026-revenue-raises-full-year-guidance-on-surging-eversense-cgm-demand 2026-06-06T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/global-rise-in-delayed-childbearing-and-infertility-drives-demand-for-cross-border-fertility-care 2026-06-06T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-rise-in-delayed-childbearing-and-infertility-drives-demand-for-cross-border-fertility-care 2026-06-06T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-multiple-myeloma-patient-seeks-car-t-cell-therapy-in-china-amid-domestic-access-gaps 2026-06-06T16:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-multiple-myeloma-patient-seeks-car-t-cell-therapy-in-china-amid-domestic-access-gaps 2026-06-06T16:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-s-sarna-candidate-lico-saucp1-demonstrates-high-quality-weight-loss-without-muscle-wasting-or-rebound-in-preclinical-obesity-models 2026-06-06T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-s-sarna-candidate-lico-saucp1-demonstrates-high-quality-weight-loss-without-muscle-wasting-or-rebound-in-preclinical-obesity-models 2026-06-06T16:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/reid-hoffman-leaves-microsoft-board-to-pursue-founder-mode-at-ai-drug-discovery-startup-manus 2026-06-06T15:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reid-hoffman-leaves-microsoft-board-to-pursue-founder-mode-at-ai-drug-discovery-startup-manus 2026-06-06T15:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/cost-effectiveness-of-genome-guided-statin-treatment-for-hypercholesterolemia 2026-06-06T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cost-effectiveness-of-genome-guided-statin-treatment-for-hypercholesterolemia 2026-06-06T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/pcsk9-inhibitors-linked-to-improved-survival-in-cancer-patients-receiving-immunotherapy-study-finds 2026-06-06T14:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcsk9-inhibitors-linked-to-improved-survival-in-cancer-patients-receiving-immunotherapy-study-finds 2026-06-06T14:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/us-measles-cases-surpass-2000-for-second-consecutive-year-elimination-status-at-risk 2026-06-06T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-measles-cases-surpass-2000-for-second-consecutive-year-elimination-status-at-risk 2026-06-06T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/redlands-community-hospital-opens-jack-and-laura-dangermond-center-for-radiation-therapy-expanding-local-cancer-care-access 2026-06-06T12:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redlands-community-hospital-opens-jack-and-laura-dangermond-center-for-radiation-therapy-expanding-local-cancer-care-access 2026-06-06T12:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-teen-cannabis-use-linked-to-reduced-brain-iron-and-dopamine-dysfunction-raising-addiction-risk 2026-06-06T11:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-teen-cannabis-use-linked-to-reduced-brain-iron-and-dopamine-dysfunction-raising-addiction-risk 2026-06-06T11:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-pipeline-momentum-key-regulatory-wins-clinical-updates-and-setbacks-reshape-outlook 2026-06-06T11:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-pipeline-momentum-key-regulatory-wins-clinical-updates-and-setbacks-reshape-outlook 2026-06-06T11:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/from-patient-to-pioneer-how-fshd-researchers-are-redefining-a-rare-disease-through-epigenetics-and-crispr 2026-06-06T10:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-patient-to-pioneer-how-fshd-researchers-are-redefining-a-rare-disease-through-epigenetics-and-crispr 2026-06-06T10:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/kgh-becomes-first-government-hospital-in-andhra-pradesh-to-offer-free-immunotherapy-for-stage-iv-lung-cancer-patients 2026-06-06T10:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kgh-becomes-first-government-hospital-in-andhra-pradesh-to-offer-free-immunotherapy-for-stage-iv-lung-cancer-patients 2026-06-06T10:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-academy-graduates-156-students-at-10th-convocation-launches-new-ai-and-dmpk-programs 2026-06-06T10:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-academy-graduates-156-students-at-10th-convocation-launches-new-ai-and-dmpk-programs 2026-06-06T10:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-cohort-launches-as-first-large-scale-longitudinal-cancer-study-focused-on-asian-americans 2026-06-06T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-cohort-launches-as-first-large-scale-longitudinal-cancer-study-focused-on-asian-americans 2026-06-06T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/liver-failure-warning-signs-recognizing-end-stage-disease-and-hepatic-encephalopathy 2026-06-06T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-failure-warning-signs-recognizing-end-stage-disease-and-hepatic-encephalopathy 2026-06-06T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/grunenthal-completes-phase-i-trial-for-first-in-class-nop-agonist-plans-phase-ii-in-acute-pain 2026-06-06T09:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grunenthal-completes-phase-i-trial-for-first-in-class-nop-agonist-plans-phase-ii-in-acute-pain 2026-06-06T09:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/spark-colorado-announces-cohort-9-nine-projects-advancing-cell-therapies-ai-tools-and-novel-biologics 2026-06-06T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spark-colorado-announces-cohort-9-nine-projects-advancing-cell-therapies-ai-tools-and-novel-biologics 2026-06-06T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/john-m-kane-receives-2026-sirs-lifetime-achievement-award-for-transformative-schizophrenia-research 2026-06-06T08:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/john-m-kane-receives-2026-sirs-lifetime-achievement-award-for-transformative-schizophrenia-research 2026-06-06T08:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-unveils-preclinical-data-for-muscle-preserving-oral-glp-1-agonist-rv-8451-at-ada-2026 2026-06-06T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rivus-pharmaceuticals-unveils-preclinical-data-for-muscle-preserving-oral-glp-1-agonist-rv-8451-at-ada-2026 2026-06-06T08:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/rogue-dna-repair-gene-exo1-creates-brca-like-vulnerability-in-multiple-cancers 2026-06-06T07:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rogue-dna-repair-gene-exo1-creates-brca-like-vulnerability-in-multiple-cancers 2026-06-06T07:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/operational-redesign-not-just-more-staff-holds-the-key-to-improving-gp-access 2026-06-06T07:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/operational-redesign-not-just-more-staff-holds-the-key-to-improving-gp-access 2026-06-06T07:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ipc-to-lead-national-materiovigilance-capacity-building-drive-at-nimhans-bengaluru 2026-06-06T05:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipc-to-lead-national-materiovigilance-capacity-building-drive-at-nimhans-bengaluru 2026-06-06T05:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/fn1-macrophages-drive-aggressive-sarcomatoid-differentiation-and-immunotherapy-resistance-in-renal-cell-carcinoma 2026-06-06T03:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fn1-macrophages-drive-aggressive-sarcomatoid-differentiation-and-immunotherapy-resistance-in-renal-cell-carcinoma 2026-06-06T03:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-cellular-reprogramming-attracts-major-investment-as-biotech-firms-target-us-610-billion-longevity-market 2026-06-06T03:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-cellular-reprogramming-attracts-major-investment-as-biotech-firms-target-us-610-billion-longevity-market 2026-06-06T03:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-faces-escalating-overdose-crisis-as-fentanyl-potency-surges-and-tranquilizer-adulterated-drugs-spread 2026-06-06T03:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-faces-escalating-overdose-crisis-as-fentanyl-potency-surges-and-tranquilizer-adulterated-drugs-spread 2026-06-06T03:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-survivorship-care-a-roadmap-for-life-after-treatment 2026-06-06T01:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-survivorship-care-a-roadmap-for-life-after-treatment 2026-06-06T01:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/ada-2026-standards-elevate-cardiorenal-risk-reduction-to-co-primary-goal-recommend-earlier-glp-1-and-sglt-2-use 2026-06-06T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ada-2026-standards-elevate-cardiorenal-risk-reduction-to-co-primary-goal-recommend-earlier-glp-1-and-sglt-2-use 2026-06-06T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/dnlitetm-assay-demonstrates-independent-renal-risk-prediction-in-landmark-credence-trial-analysis 2026-06-06T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dnlitetm-assay-demonstrates-independent-renal-risk-prediction-in-landmark-credence-trial-analysis 2026-06-06T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1s-and-the-unchanged-moral-narrative-of-thinness-a-cultural-analysis 2026-06-06T00:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1s-and-the-unchanged-moral-narrative-of-thinness-a-cultural-analysis 2026-06-06T00:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-proposes-six-month-moratorium-on-new-hospice-and-home-health-licenses-amid-fraud-investigation 2026-06-06T00:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevada-proposes-six-month-moratorium-on-new-hospice-and-home-health-licenses-amid-fraud-investigation 2026-06-06T00:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-pharma-4-0-market-projected-to-reach-usd-90-71-billion-by-2034-growing-at-19-80-cagr 2026-06-06T00:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-pharma-4-0-market-projected-to-reach-usd-90-71-billion-by-2034-growing-at-19-80-cagr 2026-06-06T00:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-precise-base-editing-of-human-embryos-achieved-but-mosaicism-and-safety-concerns-persist 2026-06-06T00:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-precise-base-editing-of-human-embryos-achieved-but-mosaicism-and-safety-concerns-persist 2026-06-06T00:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-prevails-in-talc-ovarian-cancer-lawsuit-as-los-angeles-jury-finds-no-negligence 2026-06-06T00:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-prevails-in-talc-ovarian-cancer-lawsuit-as-los-angeles-jury-finds-no-negligence 2026-06-06T00:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/new-laboratory-tool-opens-door-to-better-treatments-for-rare-and-deadly-melanomas 2026-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-laboratory-tool-opens-door-to-better-treatments-for-rare-and-deadly-melanomas 2026-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-method-reveals-hidden-self-harm-histories-in-veterans-medical-records-quadrupling-detection-rates 2026-06-05T23:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-method-reveals-hidden-self-harm-histories-in-veterans-medical-records-quadrupling-detection-rates 2026-06-05T23:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/icpr-2025-european-psychedelic-research-confronts-negative-trials-ethical-breaches-and-the-challenge-of-inclusivity 2026-06-05T23:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icpr-2025-european-psychedelic-research-confronts-negative-trials-ethical-breaches-and-the-challenge-of-inclusivity 2026-06-05T23:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-oriva-office-to-accelerate-nonanimal-human-based-research-methods 2026-06-05T22:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-oriva-office-to-accelerate-nonanimal-human-based-research-methods 2026-06-05T22:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/noveris-health-sciences-re-engages-api-for-psilocybin-drug-development-and-joins-bio 2026-06-05T22:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noveris-health-sciences-re-engages-api-for-psilocybin-drug-development-and-joins-bio 2026-06-05T22:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/ethiopia-confirms-first-marburg-virus-disease-outbreak-19-cases-64-3-fatality-rate-and-a-coordinated-international-response 2026-06-05T21:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethiopia-confirms-first-marburg-virus-disease-outbreak-19-cases-64-3-fatality-rate-and-a-coordinated-international-response 2026-06-05T21:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-proton-therapy-system-arrives-in-nebraska-ending-proton-desert-for-central-u-s-cancer-patients 2026-06-05T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-proton-therapy-system-arrives-in-nebraska-ending-proton-desert-for-central-u-s-cancer-patients 2026-06-05T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-biotech-startups-take-center-stage-at-boston-roadshow-as-us-investors-signal-selective-recovery-in-2026 2026-06-05T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-biotech-startups-take-center-stage-at-boston-roadshow-as-us-investors-signal-selective-recovery-in-2026 2026-06-05T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/study-challenges-long-held-mechanism-of-hdac-inhibitors-in-cancer-treatment 2026-06-05T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-challenges-long-held-mechanism-of-hdac-inhibitors-in-cancer-treatment 2026-06-05T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/neuronoff-implants-first-patient-in-dod-funded-trial-of-minimally-invasive-injectrode-for-neurogenic-bladder-in-spinal-cord-injury 2026-06-05T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuronoff-implants-first-patient-in-dod-funded-trial-of-minimally-invasive-injectrode-for-neurogenic-bladder-in-spinal-cord-injury 2026-06-05T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/two-nih-researchers-arrested-for-allegedly-smuggling-monkeypox-virus-samples-into-the-united-states 2026-06-05T20:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-nih-researchers-arrested-for-allegedly-smuggling-monkeypox-virus-samples-into-the-united-states 2026-06-05T20:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-unanimously-sides-with-generic-drugmakers-in-skinny-label-patent-case 2026-06-05T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-unanimously-sides-with-generic-drugmakers-in-skinny-label-patent-case 2026-06-05T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/building-the-plane-while-flying-it-operational-realities-of-cell-and-gene-therapy-program-development 2026-06-05T20:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/building-the-plane-while-flying-it-operational-realities-of-cell-and-gene-therapy-program-development 2026-06-05T20:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/stevens-johnson-syndrome-understanding-medication-triggers-timing-and-the-critical-window-for-diagnosis 2026-06-05T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stevens-johnson-syndrome-understanding-medication-triggers-timing-and-the-critical-window-for-diagnosis 2026-06-05T20:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-identifies-12-proteins-linking-cholesterol-and-inflammation-in-ischemic-heart-disease-pointing-to-dual-target-therapies 2026-06-05T19:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-identifies-12-proteins-linking-cholesterol-and-inflammation-in-ischemic-heart-disease-pointing-to-dual-target-therapies 2026-06-05T19:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/new-risk-prediction-tool-identifies-breast-cancer-survivors-most-likely-to-develop-heart-failure-within-10-years 2026-06-05T19:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-risk-prediction-tool-identifies-breast-cancer-survivors-most-likely-to-develop-heart-failure-within-10-years 2026-06-05T19:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-argenx-s-vyvgart-label-expansion-to-all-adult-gmg-patients-in-may-2026 2026-06-05T19:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-argenx-s-vyvgart-label-expansion-to-all-adult-gmg-patients-in-may-2026 2026-06-05T19:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/deadly-multi-state-listeria-outbreak-traced-to-clover-hill-dairy-soft-cheese-one-death-reported 2026-06-05T19:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deadly-multi-state-listeria-outbreak-traced-to-clover-hill-dairy-soft-cheese-one-death-reported 2026-06-05T19:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/generic-drug-industry-transformation-biosimilars-and-complex-generics-drive-new-growth-for-sandoz-teva-and-viatris 2026-06-05T19:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generic-drug-industry-transformation-biosimilars-and-complex-generics-drive-new-growth-for-sandoz-teva-and-viatris 2026-06-05T19:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxetane-to-azetidine-skeletal-editing-a-single-atom-transmutation-strategy-for-drug-discovery 2026-06-05T18:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxetane-to-azetidine-skeletal-editing-a-single-atom-transmutation-strategy-for-drug-discovery 2026-06-05T18:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/facioscapulohumeral-muscular-dystrophy-market-poised-for-transformative-growth-as-gene-targeted-therapies-advance-toward-regulatory-submissions 2026-06-05T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/facioscapulohumeral-muscular-dystrophy-market-poised-for-transformative-growth-as-gene-targeted-therapies-advance-toward-regulatory-submissions 2026-06-05T18:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-inc-receives-fda-ide-approval-to-initiate-first-in-human-study-of-radiogel-r-for-papillary-thyroid-carcinoma 2026-06-05T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivos-inc-receives-fda-ide-approval-to-initiate-first-in-human-study-of-radiogel-r-for-papillary-thyroid-carcinoma 2026-06-05T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/ai-detects-early-epilepsy-signs-in-eeg-data-without-visible-seizures 2026-06-05T18:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-detects-early-epilepsy-signs-in-eeg-data-without-visible-seizures 2026-06-05T18:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/target-recalls-up-up-baby-wipes-nationwide-after-fda-testing-detects-burkholderia-contamination 2026-06-05T18:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/target-recalls-up-up-baby-wipes-nationwide-after-fda-testing-detects-burkholderia-contamination 2026-06-05T18:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/creatine-may-supercharge-dendritic-cells-to-boost-cancer-immunotherapy-response-ucla-study-finds 2026-06-05T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creatine-may-supercharge-dendritic-cells-to-boost-cancer-immunotherapy-response-ucla-study-finds 2026-06-05T18:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/rna-based-molecular-test-more-accurately-distinguishes-active-c-difficile-infection-from-colonization 2026-06-05T18:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-based-molecular-test-more-accurately-distinguishes-active-c-difficile-infection-from-colonization 2026-06-05T18:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncology-at-a-crossroads-how-infrastructure-investment-is-reshaping-cancer-care-delivery 2026-06-05T18:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-oncology-at-a-crossroads-how-infrastructure-investment-is-reshaping-cancer-care-delivery 2026-06-05T18:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/favorable-lifestyle-factors-reduce-dementia-risk-across-key-genetic-profiles-japanese-study-finds 2026-06-05T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/favorable-lifestyle-factors-reduce-dementia-risk-across-key-genetic-profiles-japanese-study-finds 2026-06-05T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-nanoparticle-platform-delivers-full-length-antibodies-inside-cells-opening-new-frontier-for-intracellular-targets 2026-06-05T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipid-nanoparticle-platform-delivers-full-length-antibodies-inside-cells-opening-new-frontier-for-intracellular-targets 2026-06-05T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/tigit-emerges-as-a-breakthrough-second-generation-immune-checkpoint-target-to-overcome-cancer-immunotherapy-resistance 2026-06-05T17:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tigit-emerges-as-a-breakthrough-second-generation-immune-checkpoint-target-to-overcome-cancer-immunotherapy-resistance 2026-06-05T17:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/vcare-pharmatech-s-next-generation-trk-inhibitor-eratrectinib-wins-nmpa-approval-for-ntrk-fusion-positive-solid-tumors 2026-06-05T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcare-pharmatech-s-next-generation-trk-inhibitor-eratrectinib-wins-nmpa-approval-for-ntrk-fusion-positive-solid-tumors 2026-06-05T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/plants-could-serve-as-miniature-drug-factories-for-astronauts-on-deep-space-missions-uc-san-diego-study-shows 2026-06-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plants-could-serve-as-miniature-drug-factories-for-astronauts-on-deep-space-missions-uc-san-diego-study-shows 2026-06-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-subsidiary-invests-eur7-million-in-gate2brain-to-advance-first-in-class-pediatric-brain-cancer-therapy 2026-06-05T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-subsidiary-invests-eur7-million-in-gate2brain-to-advance-first-in-class-pediatric-brain-cancer-therapy 2026-06-05T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-austedo-demonstrates-real-world-quality-of-life-improvements-for-huntington-s-disease-chorea-patients-and-caregivers 2026-06-05T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-s-austedo-demonstrates-real-world-quality-of-life-improvements-for-huntington-s-disease-chorea-patients-and-caregivers 2026-06-05T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/new-proteomic-map-reveals-how-cancer-metabolism-rewires-t-cell-proteins-opening-immunotherapy-targets 2026-06-05T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-proteomic-map-reveals-how-cancer-metabolism-rewires-t-cell-proteins-opening-immunotherapy-targets 2026-06-05T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiome-emerges-as-the-next-frontier-in-cancer-care-with-landmark-probiotic-trial-set-to-launch 2026-06-05T16:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiome-emerges-as-the-next-frontier-in-cancer-care-with-landmark-probiotic-trial-set-to-launch 2026-06-05T16:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/dual-ligand-mitochondria-targeted-nanosystem-achieves-85-23-tumor-suppression-in-hepatocellular-carcinoma 2026-06-05T16:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-ligand-mitochondria-targeted-nanosystem-achieves-85-23-tumor-suppression-in-hepatocellular-carcinoma 2026-06-05T16:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/nickel-0-catalyzed-endo-stereoselective-2-2-cycloaddition-overcomes-norbornadiene-facial-bias 2026-06-05T16:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nickel-0-catalyzed-endo-stereoselective-2-2-cycloaddition-overcomes-norbornadiene-facial-bias 2026-06-05T16:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/potravitug-demonstrates-statistically-significant-viral-clearance-in-phase-ii-bk-polyomavirus-trial-paving-way-for-pivotal-phase-iii 2026-06-05T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/potravitug-demonstrates-statistically-significant-viral-clearance-in-phase-ii-bk-polyomavirus-trial-paving-way-for-pivotal-phase-iii 2026-06-05T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/flu-drugs-show-promise-against-cognitive-decline-in-hiv-patients-preclinical-study-finds 2026-06-05T16:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flu-drugs-show-promise-against-cognitive-decline-in-hiv-patients-preclinical-study-finds 2026-06-05T16:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-policy-shift-on-ebola-evacuations-raises-alarm-among-infectious-disease-experts 2026-06-05T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-policy-shift-on-ebola-evacuations-raises-alarm-among-infectious-disease-experts 2026-06-05T16:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/longbio-pharma-debuts-on-hong-kong-stock-exchange-at-hk-10-7-billion-valuation-advancing-novel-anti-ige-and-complement-targeting-biologics 2026-06-05T16:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longbio-pharma-debuts-on-hong-kong-stock-exchange-at-hk-10-7-billion-valuation-advancing-novel-anti-ige-and-complement-targeting-biologics 2026-06-05T16:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/treosulfan-based-myeloablative-conditioning-enables-donor-specific-tolerance-and-stable-mixed-chimerism-in-allogeneic-transplantation 2026-06-05T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treosulfan-based-myeloablative-conditioning-enables-donor-specific-tolerance-and-stable-mixed-chimerism-in-allogeneic-transplantation 2026-06-05T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/patients-before-monopolies-act-proposed-breakup-of-pbm-owned-pharmacies-could-reshape-drug-pricing-landscape 2026-06-05T15:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patients-before-monopolies-act-proposed-breakup-of-pbm-owned-pharmacies-could-reshape-drug-pricing-landscape 2026-06-05T15:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/antibody-fragment-eliminates-brain-haemorrhage-risk-in-alzheimer-s-immunotherapy-preclinical-study-shows 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibody-fragment-eliminates-brain-haemorrhage-risk-in-alzheimer-s-immunotherapy-preclinical-study-shows 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/actg-launches-hiv-cure-study-evaluating-dasatinib-to-target-the-hiv-reservoir 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actg-launches-hiv-cure-study-evaluating-dasatinib-to-target-the-hiv-reservoir 2026-06-05T15:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharma-enters-biosimilar-market-with-chime-biologics-partnership-for-dupixent-biosimilar 2026-06-05T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-pharma-enters-biosimilar-market-with-chime-biologics-partnership-for-dupixent-biosimilar 2026-06-05T14:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-ai-is-automating-prior-authorization-backwards-and-why-the-next-leap-must-be-proactive 2026-06-05T12:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-ai-is-automating-prior-authorization-backwards-and-why-the-next-leap-must-be-proactive 2026-06-05T12:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/preparative-and-process-chromatography-market-projected-to-reach-29-53-billion-by-2035-driven-by-biologics-manufacturing-boom 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preparative-and-process-chromatography-market-projected-to-reach-29-53-billion-by-2035-driven-by-biologics-manufacturing-boom 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-strengthens-commercial-leadership-with-appointment-of-jim-gute-as-chief-commercial-officer 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-strengthens-commercial-leadership-with-appointment-of-jim-gute-as-chief-commercial-officer 2026-06-05T12:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-of-ai-designed-universal-coronavirus-vaccine-shows-safety-broad-immune-response 2026-06-05T12:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-of-ai-designed-universal-coronavirus-vaccine-shows-safety-broad-immune-response 2026-06-05T12:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/optimal-exercise-combination-60-119-minutes-of-strength-training-plus-high-aerobic-activity-linked-to-45-58-lower-mortality-risk 2026-06-05T12:51:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimal-exercise-combination-60-119-minutes-of-strength-training-plus-high-aerobic-activity-linked-to-45-58-lower-mortality-risk 2026-06-05T12:51:03+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-half-of-dementia-cases-are-preventable-lancet-commission-identifies-14-modifiable-risk-factors 2026-06-05T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-half-of-dementia-cases-are-preventable-lancet-commission-identifies-14-modifiable-risk-factors 2026-06-05T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-leaders-and-nobel-laureates-urge-congress-to-mandate-synthetic-dna-screening-amid-growing-biosecurity-concerns 2026-06-05T11:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-leaders-and-nobel-laureates-urge-congress-to-mandate-synthetic-dna-screening-amid-growing-biosecurity-concerns 2026-06-05T11:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/bexobrutideg-shows-high-response-rates-and-manageable-safety-in-btk-degrader-trial-for-relapsed-refractory-cll 2026-06-05T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexobrutideg-shows-high-response-rates-and-manageable-safety-in-btk-degrader-trial-for-relapsed-refractory-cll 2026-06-05T11:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-blocks-colorado-s-first-in-the-nation-prescription-drug-price-cap-on-amgen-s-enbrel 2026-06-05T11:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-judge-blocks-colorado-s-first-in-the-nation-prescription-drug-price-cap-on-amgen-s-enbrel 2026-06-05T11:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-silent-inflammation-the-hidden-driver-of-autoimmune-disease-and-metabolic-decline 2026-06-05T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-silent-inflammation-the-hidden-driver-of-autoimmune-disease-and-metabolic-decline 2026-06-05T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-cro-services-market-to-reach-3-51-billion-by-2035-driven-by-oncology-trial-complexity-and-ai-integration 2026-06-05T10:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imaging-cro-services-market-to-reach-3-51-billion-by-2035-driven-by-oncology-trial-complexity-and-ai-integration 2026-06-05T10:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/madras-high-court-rules-chennai-api-maker-s-vildagliptin-exports-to-egypt-infringed-novartis-patent 2026-06-05T10:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madras-high-court-rules-chennai-api-maker-s-vildagliptin-exports-to-egypt-infringed-novartis-patent 2026-06-05T10:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-analysts-issue-mixed-ratings-on-pharma-giants-novartis-and-sanofi 2026-06-05T10:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-analysts-issue-mixed-ratings-on-pharma-giants-novartis-and-sanofi 2026-06-05T10:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/dry-amd-market-poised-for-19-2-cagr-growth-through-2036-as-pipeline-diversifies-beyond-complement-inhibition 2026-06-05T09:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dry-amd-market-poised-for-19-2-cagr-growth-through-2036-as-pipeline-diversifies-beyond-complement-inhibition 2026-06-05T09:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-tenecteplase-trial-challenges-the-4-5-hour-thrombolysis-wall-and-exposes-a-u-s-regulatory-gap 2026-06-05T08:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-tenecteplase-trial-challenges-the-4-5-hour-thrombolysis-wall-and-exposes-a-u-s-regulatory-gap 2026-06-05T08:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/kaleida-health-launches-epic-based-integrated-patient-record-system-across-western-new-york 2026-06-05T08:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaleida-health-launches-epic-based-integrated-patient-record-system-across-western-new-york 2026-06-05T08:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/the-dad-bod-dilemma-paternal-health-before-conception-may-shape-childhood-obesity-risk-uc-irvine-review-finds 2026-06-05T08:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-dad-bod-dilemma-paternal-health-before-conception-may-shape-childhood-obesity-risk-uc-irvine-review-finds 2026-06-05T08:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/ib-neuro-s-srcbv-demonstrates-superior-overall-survival-prediction-in-phase-ii-glioblastoma-trial-at-asco-2026 2026-06-05T08:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ib-neuro-s-srcbv-demonstrates-superior-overall-survival-prediction-in-phase-ii-glioblastoma-trial-at-asco-2026 2026-06-05T08:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/lkcmedicine-class-of-2026-graduates-169-new-doctors-at-convocation-ceremony 2026-06-05T08:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lkcmedicine-class-of-2026-graduates-169-new-doctors-at-convocation-ceremony 2026-06-05T08:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/falling-fentanyl-deaths-drive-historic-24-4-drop-in-u-s-overdose-mortality-but-stimulant-and-xylazine-threats-grow 2026-06-05T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/falling-fentanyl-deaths-drive-historic-24-4-drop-in-u-s-overdose-mortality-but-stimulant-and-xylazine-threats-grow 2026-06-05T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-9mw5211-receives-nmpa-and-fda-clearance-for-inflammatory-bowel-disease-clinical-trials 2026-06-05T07:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-9mw5211-receives-nmpa-and-fda-clearance-for-inflammatory-bowel-disease-clinical-trials 2026-06-05T07:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-publishes-phase-2-rainbow-study-data-for-nizubaglustat-in-gm2-gangliosidosis-and-niemann-pick-type-c-disease 2026-06-05T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-publishes-phase-2-rainbow-study-data-for-nizubaglustat-in-gm2-gangliosidosis-and-niemann-pick-type-c-disease 2026-06-05T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/cms-acute-hospital-care-at-home-program-extended-through-2030-paving-the-way-for-expanded-home-based-inpatient-care 2026-06-05T07:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-acute-hospital-care-at-home-program-extended-through-2030-paving-the-way-for-expanded-home-based-inpatient-care 2026-06-05T07:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/roche-secures-ce-mark-for-automated-elecsys-igra-tb-diagnostic-test 2026-06-05T05:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-secures-ce-mark-for-automated-elecsys-igra-tb-diagnostic-test 2026-06-05T05:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/spdr-s-p-pharmaceuticals-etf-outperforms-biotech-counterparts-with-lower-costs-and-stronger-returns 2026-06-05T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spdr-s-p-pharmaceuticals-etf-outperforms-biotech-counterparts-with-lower-costs-and-stronger-returns 2026-06-05T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/blood-protein-signature-predicts-lung-cancer-risk-more-than-five-years-before-diagnosis 2026-06-05T04:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-protein-signature-predicts-lung-cancer-risk-more-than-five-years-before-diagnosis 2026-06-05T04:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-moves-from-experimentation-to-clinical-operations-raising-new-security-and-governance-challenges 2026-06-05T04:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agentic-ai-moves-from-experimentation-to-clinical-operations-raising-new-security-and-governance-challenges 2026-06-05T04:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-real-time-release-of-complete-response-letters-faces-legal-challenge-over-transparency-push 2026-06-05T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-real-time-release-of-complete-response-letters-faces-legal-challenge-over-transparency-push 2026-06-05T03:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/usaid-dismantling-cripples-ebola-response-in-dr-congo-as-bundibugyo-outbreak-spreads 2026-06-05T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usaid-dismantling-cripples-ebola-response-in-dr-congo-as-bundibugyo-outbreak-spreads 2026-06-05T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/mesenchymal-stem-cells-market-to-reach-usd-9-08-billion-by-2031-growing-at-12-cagr 2026-06-05T03:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesenchymal-stem-cells-market-to-reach-usd-9-08-billion-by-2031-growing-at-12-cagr 2026-06-05T03:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-cancer-into-a-chronic-condition-as-survival-rates-hit-record-highs 2026-06-05T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapies-transform-cancer-into-a-chronic-condition-as-survival-rates-hit-record-highs 2026-06-05T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/establishing-ctdna-as-a-validated-primary-surrogate-endpoint-in-solid-tumour-oncology 2026-06-05T01:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/establishing-ctdna-as-a-validated-primary-surrogate-endpoint-in-solid-tumour-oncology 2026-06-05T01:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-landscape-of-rare-variants-in-a-chinese-autism-cohort-reveals-novel-risk-genes 2026-06-05T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-landscape-of-rare-variants-in-a-chinese-autism-cohort-reveals-novel-risk-genes 2026-06-05T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-surges-on-fda-approval-of-decnupaz-for-rare-blood-cancer-and-european-nod-for-migraine-therapy 2026-06-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-surges-on-fda-approval-of-decnupaz-for-rare-blood-cancer-and-european-nod-for-migraine-therapy 2026-06-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-government-proposes-landmark-reform-to-medicinal-cannabis-driving-laws-with-three-strike-warning-system 2026-06-05T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsw-government-proposes-landmark-reform-to-medicinal-cannabis-driving-laws-with-three-strike-warning-system 2026-06-05T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/common-hypertension-drugs-linked-to-worse-kidney-outcomes-in-type-2-diabetes-patients-despite-modern-therapies 2026-06-05T00:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/common-hypertension-drugs-linked-to-worse-kidney-outcomes-in-type-2-diabetes-patients-despite-modern-therapies 2026-06-05T00:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-antibody-discovery-market-to-reach-usd-3-16-billion-by-2034-growing-at-21-57-cagr 2026-06-04T23:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-antibody-discovery-market-to-reach-usd-3-16-billion-by-2034-growing-at-21-57-cagr 2026-06-04T23:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/eic-pavilion-to-showcase-european-biotech-innovators-at-bio-2026-international-convention 2026-06-04T23:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eic-pavilion-to-showcase-european-biotech-innovators-at-bio-2026-international-convention 2026-06-04T23:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/unodc-launches-international-standards-workshop-to-strengthen-drug-use-disorder-treatment-in-southern-africa 2026-06-04T23:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unodc-launches-international-standards-workshop-to-strengthen-drug-use-disorder-treatment-in-southern-africa 2026-06-04T23:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/clear-protein-emerges-as-popular-lactose-free-alternative-to-traditional-whey-powders 2026-06-04T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clear-protein-emerges-as-popular-lactose-free-alternative-to-traditional-whey-powders 2026-06-04T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/hscc-releases-ai-governance-framework-for-healthcare-warning-of-clinical-risks-including-fatal-hallucinations 2026-06-04T22:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hscc-releases-ai-governance-framework-for-healthcare-warning-of-clinical-risks-including-fatal-hallucinations 2026-06-04T22:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-receives-nasdaq-non-compliance-notice-over-minimum-bid-price-deficiency 2026-06-04T22:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhengye-biotechnology-receives-nasdaq-non-compliance-notice-over-minimum-bid-price-deficiency 2026-06-04T22:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/acting-fda-commissioner-kyle-diamantas-meets-with-rare-disease-groups-to-repair-strained-relations 2026-06-04T22:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acting-fda-commissioner-kyle-diamantas-meets-with-rare-disease-groups-to-repair-strained-relations 2026-06-04T22:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/senate-hearing-exposes-systemic-failures-in-generic-drug-supply-chain-raising-safety-concerns-for-millions-of-americans 2026-06-04T22:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-hearing-exposes-systemic-failures-in-generic-drug-supply-chain-raising-safety-concerns-for-millions-of-americans 2026-06-04T22:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/shapiro-administration-pushes-100-million-innovate-in-pa-2-0-fund-to-accelerate-life-sciences-and-healthcare-innovation 2026-06-04T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shapiro-administration-pushes-100-million-innovate-in-pa-2-0-fund-to-accelerate-life-sciences-and-healthcare-innovation 2026-06-04T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/pde4b-emerges-as-shared-therapeutic-target-across-tissues-in-systemic-sclerosis 2026-06-04T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pde4b-emerges-as-shared-therapeutic-target-across-tissues-in-systemic-sclerosis 2026-06-04T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/senate-hearing-spotlights-unresolved-debate-over-mrna-covid-vaccines-and-cancer-risk 2026-06-04T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-hearing-spotlights-unresolved-debate-over-mrna-covid-vaccines-and-cancer-risk 2026-06-04T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/study-offers-cautious-reassurance-on-first-trimester-nsaid-use-and-congenital-malformation-risk 2026-06-04T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-offers-cautious-reassurance-on-first-trimester-nsaid-use-and-congenital-malformation-risk 2026-06-04T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/eu-introduces-mandatory-harmonised-template-for-clinical-trial-recruitment-and-informed-consent-under-ctr 2026-06-04T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-introduces-mandatory-harmonised-template-for-clinical-trial-recruitment-and-informed-consent-under-ctr 2026-06-04T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/remote-work-linked-to-increased-isolation-and-mental-health-decline-in-large-scale-us-study 2026-06-04T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-work-linked-to-increased-isolation-and-mental-health-decline-in-large-scale-us-study 2026-06-04T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-launches-enhanced-dna-to-ind-programme-with-gs-ori-go-vector-technology-to-accelerate-biologics-development 2026-06-04T20:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-launches-enhanced-dna-to-ind-programme-with-gs-ori-go-vector-technology-to-accelerate-biologics-development 2026-06-04T20:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/scispot-raises-8m-series-a-to-build-ai-native-operating-layer-for-life-sciences-labs 2026-06-04T20:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scispot-raises-8m-series-a-to-build-ai-native-operating-layer-for-life-sciences-labs 2026-06-04T20:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/haleon-issues-voluntary-nationwide-recall-of-gas-x-extra-strength-softgels-due-to-potential-coolant-contamination 2026-06-04T20:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haleon-issues-voluntary-nationwide-recall-of-gas-x-extra-strength-softgels-due-to-potential-coolant-contamination 2026-06-04T20:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/cross-reactive-t-cells-discovered-to-target-paramyxovirus-family-offering-broad-protection-against-measles-and-nipah-virus 2026-06-04T20:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cross-reactive-t-cells-discovered-to-target-paramyxovirus-family-offering-broad-protection-against-measles-and-nipah-virus 2026-06-04T20:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapies-by-leveraging-prior-knowledge 2026-06-04T20:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapies-by-leveraging-prior-knowledge 2026-06-04T20:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/multiomics-the-systems-approach-reshaping-drug-discovery-and-precision-medicine 2026-06-04T20:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiomics-the-systems-approach-reshaping-drug-discovery-and-precision-medicine 2026-06-04T20:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/california-research-bond-for-ucsb-and-uc-system-fails-to-qualify-for-november-ballot-amid-federal-funding-crisis 2026-06-04T20:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-research-bond-for-ucsb-and-uc-system-fails-to-qualify-for-november-ballot-amid-federal-funding-crisis 2026-06-04T20:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-canada-partners-with-nova-scotia-health-innovation-hub-to-accelerate-clinical-research-and-patient-access-to-trials 2026-06-04T19:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-canada-partners-with-nova-scotia-health-innovation-hub-to-accelerate-clinical-research-and-patient-access-to-trials 2026-06-04T19:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/borrelia-mayonii-lyme-disease-detected-in-new-york-for-the-first-time-raising-concerns-about-geographic-spread 2026-06-04T19:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/borrelia-mayonii-lyme-disease-detected-in-new-york-for-the-first-time-raising-concerns-about-geographic-spread 2026-06-04T19:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/evosep-launches-evosep-proteomics-ecosystem-to-standardize-lc-ms-based-proteomics-for-drug-development 2026-06-04T18:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evosep-launches-evosep-proteomics-ecosystem-to-standardize-lc-ms-based-proteomics-for-drug-development 2026-06-04T18:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/oncovita-unveils-promising-preclinical-data-for-mvdeltac-a-modified-measles-virus-immunotherapy-at-eacr-2026 2026-06-04T18:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncovita-unveils-promising-preclinical-data-for-mvdeltac-a-modified-measles-virus-immunotherapy-at-eacr-2026 2026-06-04T18:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-tmb-outperforms-blood-based-testing-for-predicting-immunotherapy-response-cleveland-clinic-study-confirms 2026-06-04T18:08:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-tmb-outperforms-blood-based-testing-for-predicting-immunotherapy-response-cleveland-clinic-study-confirms 2026-06-04T18:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-and-fountain-life-launch-investigational-placental-cell-therapy-cenplacel-l-in-florida-under-novel-state-regulatory-framework 2026-06-04T18:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-and-fountain-life-launch-investigational-placental-cell-therapy-cenplacel-l-in-florida-under-novel-state-regulatory-framework 2026-06-04T18:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-and-boehringer-halt-2bn-german-investments-as-pharma-industry-protests-drug-spending-curbs 2026-06-04T18:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-and-boehringer-halt-2bn-german-investments-as-pharma-industry-protests-drug-spending-curbs 2026-06-04T18:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-issues-drug-safety-update-for-ace-inhibitors-amid-chronic-medicine-shortages 2026-06-04T18:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-issues-drug-safety-update-for-ace-inhibitors-amid-chronic-medicine-shortages 2026-06-04T18:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-flags-gsk-s-oncology-pipeline-as-major-value-driver-with-four-near-term-catalysts-in-2026 2026-06-04T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-flags-gsk-s-oncology-pipeline-as-major-value-driver-with-four-near-term-catalysts-in-2026 2026-06-04T18:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/adocia-to-host-virtual-kol-event-reviewing-phase-3-results-of-ultra-rapid-insulin-biochaperone-lispro-in-type-2-diabetes 2026-06-04T18:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adocia-to-host-virtual-kol-event-reviewing-phase-3-results-of-ultra-rapid-insulin-biochaperone-lispro-in-type-2-diabetes 2026-06-04T18:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-1-in-5-young-people-turn-to-ai-chatbots-for-mental-health-support-rand-study-finds 2026-06-04T17:11:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-1-in-5-young-people-turn-to-ai-chatbots-for-mental-health-support-rand-study-finds 2026-06-04T17:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/frontiers-launches-research-topic-on-personalized-approaches-in-gynecologic-oncology-highlighting-precision-medicine-and-rare-tumor-challenges 2026-06-04T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frontiers-launches-research-topic-on-personalized-approaches-in-gynecologic-oncology-highlighting-precision-medicine-and-rare-tumor-challenges 2026-06-04T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/obe-cel-shows-superior-efficacy-over-standard-of-care-in-matched-analysis-for-r-r-b-all 2026-06-04T17:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obe-cel-shows-superior-efficacy-over-standard-of-care-in-matched-analysis-for-r-r-b-all 2026-06-04T17:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-debug-project-seeks-epa-approval-to-release-64-million-wolbachia-infected-mosquitoes-in-california-and-florida 2026-06-04T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-debug-project-seeks-epa-approval-to-release-64-million-wolbachia-infected-mosquitoes-in-california-and-florida 2026-06-04T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-let-s-talk-trials-initiative-to-address-persistent-gaps-in-clinical-trial-representation 2026-06-04T17:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-launches-let-s-talk-trials-initiative-to-address-persistent-gaps-in-clinical-trial-representation 2026-06-04T17:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/saliva-biomarkers-can-directly-detect-acute-sleep-deprivation-paving-way-for-roadside-fatigue-testing 2026-06-04T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saliva-biomarkers-can-directly-detect-acute-sleep-deprivation-paving-way-for-roadside-fatigue-testing 2026-06-04T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-key-alzheimer-s-tipping-point-in-microglia-that-may-determine-who-gets-dementia 2026-06-04T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-discover-key-alzheimer-s-tipping-point-in-microglia-that-may-determine-who-gets-dementia 2026-06-04T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-first-human-trial-of-mitragynine-for-opioid-use-disorder 2026-06-04T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-first-human-trial-of-mitragynine-for-opioid-use-disorder 2026-06-04T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-protein-signature-predicts-organ-specific-aging-and-disease-risk-stanford-study-shows 2026-06-04T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-protein-signature-predicts-organ-specific-aging-and-disease-risk-stanford-study-shows 2026-06-04T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/cerevasc-secures-85-million-series-c-to-advance-minimally-invasive-eshunt-system-for-normal-pressure-hydrocephalus 2026-06-04T17:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevasc-secures-85-million-series-c-to-advance-minimally-invasive-eshunt-system-for-normal-pressure-hydrocephalus 2026-06-04T17:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-cdmo-market-projected-to-reach-52-8-billion-by-2034-growing-at-24-5-cagr 2026-06-04T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-cdmo-market-projected-to-reach-52-8-billion-by-2034-growing-at-24-5-cagr 2026-06-04T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-strong-buy-consensus-on-eli-lilly-amid-conflicting-healthcare-sector-sentiments 2026-06-04T17:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-strong-buy-consensus-on-eli-lilly-amid-conflicting-healthcare-sector-sentiments 2026-06-04T17:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/florida-launches-first-in-nation-newborn-whole-genome-sequencing-program-to-detect-nearly-900-rare-diseases 2026-06-04T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-launches-first-in-nation-newborn-whole-genome-sequencing-program-to-detect-nearly-900-rare-diseases 2026-06-04T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-rocbrutinib-a-dual-mode-btk-inhibitor-for-drug-resistant-lymphoma 2026-06-04T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-rocbrutinib-a-dual-mode-btk-inhibitor-for-drug-resistant-lymphoma 2026-06-04T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/notch2-and-cxcr4-identified-as-key-drivers-of-breast-cancer-dormancy-in-bone-marrow 2026-06-04T16:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/notch2-and-cxcr4-identified-as-key-drivers-of-breast-cancer-dormancy-in-bone-marrow 2026-06-04T16:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/hdbuzz-2025-annual-report-independent-hd-science-journalism-reaches-329000-visitors-amid-accelerating-research 2026-06-04T16:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdbuzz-2025-annual-report-independent-hd-science-journalism-reaches-329000-visitors-amid-accelerating-research 2026-06-04T16:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/melinda-french-gates-commits-additional-215-million-to-women-s-health-targeting-midlife-and-menopause 2026-06-04T16:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/melinda-french-gates-commits-additional-215-million-to-women-s-health-targeting-midlife-and-menopause 2026-06-04T16:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/five-years-of-the-global-diabetes-compact-progress-persistent-gaps-and-the-fight-for-universal-insulin-access 2026-06-04T16:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-years-of-the-global-diabetes-compact-progress-persistent-gaps-and-the-fight-for-universal-insulin-access 2026-06-04T16:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/ladenburg-thalmann-expands-biotechnology-equity-research-team-with-two-senior-analysts 2026-06-04T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ladenburg-thalmann-expands-biotechnology-equity-research-team-with-two-senior-analysts 2026-06-04T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/princess-of-wales-visits-cancer-patients-at-the-christie-nhs-foundation-trust-highlighting-holistic-support-services 2026-06-04T16:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/princess-of-wales-visits-cancer-patients-at-the-christie-nhs-foundation-trust-highlighting-holistic-support-services 2026-06-04T16:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/retail-giants-turn-glp-1-prescriptions-into-long-term-customer-relationships-as-employer-coverage-declines 2026-06-04T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retail-giants-turn-glp-1-prescriptions-into-long-term-customer-relationships-as-employer-coverage-declines 2026-06-04T16:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-and-refeyn-launch-first-integrated-workflow-for-bispecific-antibody-and-biosimilar-characterization 2026-06-04T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-and-refeyn-launch-first-integrated-workflow-for-bispecific-antibody-and-biosimilar-characterization 2026-06-04T16:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/cfr-report-warns-u-s-pharmaceutical-supply-chain-faces-rare-earths-level-threat-from-chinese-dependence 2026-06-04T16:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cfr-report-warns-u-s-pharmaceutical-supply-chain-faces-rare-earths-level-threat-from-chinese-dependence 2026-06-04T16:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/the-ai-cancer-cure-debate-promise-skepticism-and-the-broader-stakes-of-superhuman-intelligence 2026-06-04T16:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-ai-cancer-cure-debate-promise-skepticism-and-the-broader-stakes-of-superhuman-intelligence 2026-06-04T16:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-named-to-newsweek-s-world-s-best-specialized-hospitals-list-for-oncology 2026-06-04T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roswell-park-named-to-newsweek-s-world-s-best-specialized-hospitals-list-for-oncology 2026-06-04T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/leonabio-unveils-phase-2-plans-for-brelgometon-ath-1105-in-als-highlighting-biomarker-driven-trial-design-at-summit 2026-06-04T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leonabio-unveils-phase-2-plans-for-brelgometon-ath-1105-in-als-highlighting-biomarker-driven-trial-design-at-summit 2026-06-04T14:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-ranked-no-1-for-patient-engagement-in-rare-diseases-for-second-consecutive-year 2026-06-04T14:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-ranked-no-1-for-patient-engagement-in-rare-diseases-for-second-consecutive-year 2026-06-04T14:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-unveils-pivotal-phase-3-garetosmab-data-in-fop-as-fda-priority-review-underway-alongside-metabolic-and-ophthalmology-pipeline-advances 2026-06-04T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-unveils-pivotal-phase-3-garetosmab-data-in-fop-as-fda-priority-review-underway-alongside-metabolic-and-ophthalmology-pipeline-advances 2026-06-04T14:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/quetiapine-improves-sleep-in-obstructive-sleep-apnea-but-impairs-next-day-driving-performance-small-trial-finds 2026-06-04T14:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quetiapine-improves-sleep-in-obstructive-sleep-apnea-but-impairs-next-day-driving-performance-small-trial-finds 2026-06-04T14:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/measles-not-ebola-tops-infectious-disease-concerns-for-2026-fifa-world-cup-health-officials-say 2026-06-04T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measles-not-ebola-tops-infectious-disease-concerns-for-2026-fifa-world-cup-health-officials-say 2026-06-04T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/attralus-zamubafusp-alfa-receives-fda-orphan-drug-designation-for-al-amyloidosis 2026-06-04T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attralus-zamubafusp-alfa-receives-fda-orphan-drug-designation-for-al-amyloidosis 2026-06-04T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/rossium-subsidiary-seeks-russian-registration-for-second-canakinumab-biosimilar-after-belarus-approval 2026-06-04T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rossium-subsidiary-seeks-russian-registration-for-second-canakinumab-biosimilar-after-belarus-approval 2026-06-04T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/kexing-biopharm-doses-first-subject-in-phase-i-trial-of-bispecific-antibody-gb10-for-neovascular-amd 2026-06-04T12:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kexing-biopharm-doses-first-subject-in-phase-i-trial-of-bispecific-antibody-gb10-for-neovascular-amd 2026-06-04T12:06:27+00:00 hourly 0.9